Peptides as antimicrobial agents towards campylobacter spp

ABSTRACT

The present invention relates to peptides that exhibit antimicrobial properties towards  Campylobacter  spp, compositions comprising such peptides, the use of such peptides for inhibiting growth of or killing  Campylobacter  spp. and for the diagnosis, prevention and treatment of  Campylobacter  infection.

FIELD OF THE INVENTION

The present invention relates to peptides that exhibit antimicrobialproperties towards Campylobacter spp, compositions comprising suchpeptides, the use of such peptides for inhibiting growth of or killingCampylobacter spp. and for the diagnosis, prevention and treatment ofCampylobacter infection.

BACKGROUND OF THE INVENTION

Campylobacter jejuni is a leading cause of sporadic food-borne illnessin humans (Altekruse et al. 1999; Wren et al. 2001). The majority ofdiagnosed Campylobacter infections are due to C. jejuni (95%) withCampylobacter coli being a less frequent cause of disease. For mostpeople, infection usually results in a moderate diarrhoeal disease;however, severe and prolonged illness is likely to occur in people withweakened, under-developed or suppressed immune systems (e.g. children,elderly and people with chronic illnesses). These cases often requiretherapeutic intervention; however, over the last decade C. jejuni hasbecome increasingly resistant to antibiotics such as tetracycline,nalidixic acid and fluorquinolones (Prats et al. 2000; Ge et al. 2003;Gupta et al. 2004), making infections harder to treat. In approximately0.1% of cases, C. jejuni infection can lead to chronic illnesses such asGuillain-Barré Syndrome (GBS), Miller-Fisher Syndrome or reactivearthritis.

Chicken meat is a major source of infection for humans (Wallace et al.1998; Altekruse et al. 1999), with the handling and consumption of rawand under-cooked poultry products being a major risk factor forcampylobacteriosis in humans. Retail chicken meat is often surfacecontaminated with thermophilic Campylobacter spp., with levels ofcontamination reported to be between 10³-10⁷ CFU/carcass (Cason et al.1997; Altekruse et al. 1999). In contrast, a lower prevalence ofCampylobacter spp. have been isolated from other meats (e.g. beef, 0.5%;pork 1.5%) (Zhao et al. 2001).

Campylobacter resides as part of the normal gastrointestinal microfloraspecies of livestock species such as poultry, with approximately 70-90%of poultry flocks becoming colonised by 4-7 weeks of age (Denis et al.2001; Evans & Sayers 2000). Various studies carried out at abattoirsindicate that during processing, the principal spread of C. jejuni isfrom the gastrointestinal tract onto the surface of dressed carcasses(Rivoal et al. 1999; Berrang et al. 2000; Musgrove et al. 1997). Itssubsequent removal from meat products is incredibly difficult due to thenature of its interaction with the skin (Northcutt et al. 2004).

Current strategies for preventing Campylobacter colonisation are provingineffective. For example, Campylobacter is ubiquitously present in manyfarm animals, pets and birds, making infection in a commercial settingalmost impossible to prevent through conventional biosecurity measures.Several other prevention strategies proposed to reduce colonisation inchickens do not offer much in practical significance. For example,probiotic treatment of chickens with lactic acid bacteria andcompetitive exclusion with beneficial microflora only reducescolonisation by 2-27% (Morishita et al. 1997; Stern et al. 2005).Conventional experimental vaccines are also hampered by the largeserotype diversity of C. jejuni strains. Current antibiotics, designedfor human medicine, generally have a broad-spectrum of activity and fallinto a relatively small number of classes with respect to mechanisms ofaction. Consequently, chickens fed these antibiotics can be a reservoirfor antibiotic-resistant bacteria in the gastrointestinal tract, whichcould be transmitted to humans via contaminated poultry in the retailstore.

There remains a need for alternative antimicrobial compounds forreducing colonisation and growth of Campylobacter spp. and for diagnosisof infection.

SUMMARY OF THE INVENTION

In one aspect, the present invention relates to an isolated peptidewhich binds to Campylobacter spp., wherein the peptide is selected fromthe group consisting of: a) a peptide comprising the amino acid sequenceEGVLGAALSAFSFDS (SEQ ID NO: 1) or a fragment thereof which is capable ofbinding to Campylobacter spp; b) a peptide comprising the amino acidsequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereof which iscapable of binding to Campylobacter spp; c) a peptide comprising theamino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or a fragment thereofwhich is capable of binding to Campylobacter spp; d) a peptidecomprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO: 4) or afragment thereof which is capable of binding to Campylobacter spp; e) apeptide comprising the amino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO:5) or a fragment thereof which is capable of binding to Campylobacterspp; f) a peptide comprising the amino acid sequence TCNLSDYTLPRARVL(SEQ ID NO: 6) or a fragment thereof which is capable of binding toCampylobacter spp; g) a peptide comprising the amino acid sequenceNFLCPSPYPKVQPGL (SEQ ID NO: 7) or a fragment thereof which is capable ofbinding to Campylobacter spp; h) a peptide comprising the amino acidsequence VPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof which iscapable of binding to Campylobacter spp; i) a peptide comprising theamino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or a fragment thereofwhich is capable of binding to Campylobacter spp; j) a peptidecomprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO: 10) or afragment thereof which is capable of binding to Campylobacter spp; k) apeptide comprising the amino acid sequence LPFNLAKPELYIFVQ (SEQ ID NO:11) or a fragment thereof which is capable of binding to Campylobacterspp; 1) a peptide comprising the amino acid sequence GRFLIRVTSSPLGPD(SEQ ID NO: 12) or a fragment thereof which is capable of binding toCampylobacter spp; m) a peptide comprising the amino acid sequenceTGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which is capableof binding to Campylobacter spp; n) a peptide comprising the amino acidsequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragment thereof which iscapable of binding to Campylobacter spp; o) a peptide comprising theamino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15) or a fragmentthereof which is capable of binding to Campylobacter spp; p) a peptidecomprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16) or afragment thereof which is capable of binding to Campylobacter spp; q) apeptide comprising the amino acid sequence VLAWFSPLTLESSRL (SEQ ID NO:17) or a fragment thereof which is capable of binding to Campylobacterspp; r) a peptide comprising the amino acid sequence VIDLSGTRKSSSGTM(SEQ ID NO: 18) or a fragment thereof which is capable of binding toCampylobacter spp; s) a peptide comprising the amino acid sequenceVRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragment thereof which is capableof binding to Campylobacter spp; t) a peptide comprising the amino acidsequence TPPYRAALATPVLLL (SEQ ID NO: 20) or a fragment thereof which iscapable of binding to Campylobacter spp; u) a peptide comprising theamino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21) or a fragmentthereof which is capable of binding to Campylobacter spp; v) a peptidecomprising the amino acid sequence HRPVKTPANAPTTMM (SEQ ID NO: 22) or afragment thereof which is capable of binding to Campylobacter spp; w) apeptide comprising the amino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO:23) or a fragment thereof which is capable of binding to Campylobacterspp; x) a peptide comprising the amino acid sequence AHAPCSLFFPLSLRP(SEQ ID NO: 24) or a fragment thereof which is capable of binding toCampylobacter spp; y.) a peptide comprising the amino acid sequenceKALYALHVPSMQVFA (SEQ ID NO: 25) or a fragment thereof which is capableof binding to Campylobacter spp; z) a peptide comprising the amino acidsequence RPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragment thereof which iscapable of binding to Campylobacter spp; and aa) a peptide comprisingthe amino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27) or a fragmentthereof which is capable of binding to Campylobacter spp.

In one embodiment, the peptide binds specifically to Campylobacter spp.

In another aspect, the present invention relates to a method ofinhibiting growth of or killing a Campylobacter species comprisingcontacting the species with one or more peptides in an amount sufficientto inhibit growth of or kill the species, wherein the one or morepeptides are selected from the group consisting of: a) a peptidecomprising the amino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; b) a peptide comprising the amino acid sequenceQAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; c) a peptidecomprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; e) a peptidecomprising the amino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; f) a peptide comprising the amino acid sequenceTCNLSDYTLPRARVL (SEQ ID NO: 6) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; g) a peptidecomprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; h) a peptide comprising the amino acid sequenceVPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; k) a peptidecomprising the amino acid sequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; 1) a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; m) a peptidecomprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; n) a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; o) a peptidecomprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; q) a peptidecomprising the amino acid sequence VLAWFSPLTLESSRL (SEQ ID NO: 17) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; r) a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; s) a peptidecomprising the amino acid sequence VRKTTSHPPSYALLH (SEQ ID NO: 19) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; t) a peptide comprising the amino acid sequenceTPPYRAALATPVLLL (SEQ ID NO: 20) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; u) a peptidecomprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; w) a peptidecomprising the amino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; x) a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; y) a peptidecomprising the amino acid sequence KALYALHVPSMQVFA (SEQ ID NO: 25) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; z) a peptide comprising the amino acid sequenceRPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; and aa) a peptidecomprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp.

In one embodiment, the one or more peptides bind to the Campylobacterspecies to inhibit growth of the Campylobacter species. The peptide maybind specifically to the Campylobacter spp to inhibit growth of theCampylobacter species.

In one embodiment, the one or more peptides bind to the Campylobacterspecies to kill the Campylobacter species. The peptide may bindspecifically to the Campylobacter spp to kill the Campylobacter species.

The Campylobacter spp. may be any species of Campylobacter. In oneembodiment, the Campylobacter spp. is Campylobacter jejuni. In anotherembodiment, the Campylobacter spp. is Campylobacter coli.

In one embodiment, the one or more peptides is a peptide comprising theamino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1), or a fragmentthereof which is capable of inhibiting growth of or killingCampylobacter spp. In one embodiment, the one or more peptides is apeptide comprising the amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO:2) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence STALPLWSNYSYDSA (SEQ IDNO: 3) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ IDNO: 4) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence KAIAFQSSPGSPVLL (SEQ IDNO: 5) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence TCNLSDYTLPRARVL (SEQ IDNO: 6) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ IDNO: 7) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence VPESIHKASLVCYRF (SEQ IDNO: 8) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence SRPIARFYTWSQNTT (SEQ IDNO: 9) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQ IDNO: 10) or a fragment thereof which is capable of inhibiting growth ofor killing Campylobacter spp. In one embodiment, the one or morepeptides is a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ(SEQ ID NO: 11) or a fragment thereof which is capable of inhibitinggrowth of or killing Campylobacter spp. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp.

In one embodiment, the one or more peptides is a peptide comprising theamino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragmentthereof which is capable of inhibiting growth of or killingCampylobacter spp. In one embodiment, the one or more peptides is apeptide comprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO:14) or a fragment thereof which is capable of inhibiting growth of orkilling Campylobacter spp. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQ IDNO: 15) or a fragment thereof which is capable of inhibiting growth ofor killing Campylobacter spp. In one embodiment, the one or morepeptides is a peptide comprising the amino acid sequence FLSDPPAPPTSPGVV(SEQ ID NO: 16), or a fragment thereof which is capable of inhibitinggrowth of or killing Campylobacter spp. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceVLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceVRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceTPPYRAALATPVLLL (SEQ ID NO: 20) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceLSAPSPMFLPPVNPH (SEQ ID NO: 21) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceCFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceKALYALHVPSMQVFA (SEQ ID NO: 25) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceRPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp. In one embodiment,the one or more peptides is a peptide comprising the amino acid sequenceKVQIIPKDTLAPLPP (SEQ ID NO: 27) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp.

In one embodiment, the method comprises inhibiting growth of or killingCampylobacter spp. in a solution. The solution may be any solution whichis capable of becoming contaminated with Campylobacter spp. In oneembodiment the solution is a solution produced in chicken processing ora solution associated with chicken production such as drinking water,water in air-conditioning units and so on.

In another embodiment, the method comprises inhibiting growth of orkilling Campylobacter spp. on a surface. The surface may be any surfacewhich is capable of becoming contaminated with Campylobacter spp. Thesurface may be a surface of agricultural equipment or equipment for useon poultry farms such as crates for transporting chickens, cages, fooddishes and equipment for use in slaughter houses e.g equipment used forslaughtering chickens; on poultry meat and on the packaging. Forexample, the surface may be a surface of a piece of equipment that comesinto contact with poultry or meat products. The surface may be a surfaceof an animal. In one embodiment, the surface is a surface of animalmeat. For example, chicken meat.

In another aspect, the present invention relates to a method ofpreventing a Campylobacter spp. infection in a subject comprisingadministering to the subject one or more peptides in an amountsufficient to prevent infection in the subject, wherein the one or morepeptides are selected from the group consisting of: a) a peptidecomprising the amino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1) or afragment thereof which is capable of preventing Campylobacter sppinfection; b) a peptide comprising the amino acid sequenceQAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereof which is capable ofpreventing Campylobacter spp infection; c) a peptide comprising theamino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or a fragment thereofwhich is capable of preventing Campylobacter spp infection; d) a peptidecomprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO: 4) or afragment thereof which is capable of preventing Campylobacter sppinfection; e) a peptide comprising the amino acid sequenceKAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereof which is capable ofpreventing Campylobacter spp infection; f) a peptide comprising theamino acid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or a fragment thereofwhich is capable of preventing Campylobacter spp infection; g) a peptidecomprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or afragment thereof which is capable of preventing Campylobacter sppinfection; h) a peptide comprising the amino acid sequenceVPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof which is capable ofpreventing Campylobacter spp infection; i) a peptide comprising theamino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or a fragment thereofwhich is capable of preventing Campylobacter spp infection; j) a peptidecomprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO: 10) or afragment thereof which is capable preventing Campylobacter sppinfection; k) a peptide comprising the amino acid sequenceLPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragment thereof which is capableof preventing Campylobacter spp infection; 1) a peptide comprising theamino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragmentthereof which is capable of preventing Campylobacter spp infection; m) apeptide comprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO:13) or a fragment thereof which is capable of preventing Campylobacterspp infection; n) a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragment thereof which is capableof preventing Campylobacter spp infection; o) a peptide comprising theamino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15) or a fragmentthereof which is capable of preventing Campylobacter spp infection; p) apeptide comprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO:16) or a fragment thereof which is capable of preventing Campylobacterspp infection; q) a peptide comprising the amino acid sequenceVLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragment thereof which is capableof preventing Campylobacter spp infection; r) a peptide comprising theamino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragmentthereof which is capable of preventing Campylobacter spp infection; s) apeptide comprising the amino acid sequence VRKTTSHPPSYALLH (SEQ ID NO:19) or a fragment thereof which is capable of preventing Campylobacterspp infection; t) a peptide comprising the amino acid sequenceTPPYRAALATPVLLL (SEQ ID NO: 20) or a fragment thereof which is capableof preventing Campylobacter spp infection; u) a peptide comprising theamino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21) or a fragmentthereof which is capable of preventing Campylobacter spp infection; v) apeptide comprising the amino acid sequence HRPVKTPANAPTTMM (SEQ ID NO:22) or a fragment thereof which is capable of preventing Campylobacterspp infection; w) a peptide comprising the amino acid sequenceCFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragment thereof which is capableof preventing Campylobacter spp infection; x) a peptide comprising theamino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragmentthereof which is capable of preventing Campylobacter spp infection; y) apeptide comprising the amino acid sequence KALYALHVPSMQVFA (SEQ ID NO:25) or a fragment thereof which is capable of preventing Campylobacterspp infection; z) a peptide comprising the amino acid sequenceRPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragment thereof which is capableof preventing Campylobacter spp infection; and aa) a peptide comprisingthe amino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27) or a fragmentthereof which is capable of preventing Campylobacter spp infection.

In another aspect, the present invention relates to a method of treatinga Campylobacter spp. infection in a subject comprising administering tothe subject one or more peptides in an amount sufficient to treat theinfection in the subject, wherein the one or more peptides are selectedfrom the group consisting of: a) a peptide comprising the amino acidsequence EGVLGAALSAFSFDS (SEQ ID NO: 1) or a fragment thereof which iscapable of treating Campylobacter spp infection; b) a peptide comprisingthe amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragmentthereof which is capable of treating Campylobacter spp infection; c) apeptide comprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO:3) or a fragment thereof which is capable of treating Campylobacter sppinfection; d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof which is capable oftreating Campylobacter spp infection; e) a peptide comprising the aminoacid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereof whichis capable of treating Campylobacter spp infection; f) a peptidecomprising the amino acid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or afragment thereof which is capable of treating Campylobacter sppinfection; g) a peptide comprising the amino acid sequenceNFLCPSPYPKVQPGL (SEQ ID NO: 7) or a fragment thereof which is capable oftreating Campylobacter spp infection; h) a peptide comprising the aminoacid sequence VPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof whichis capable of treating Campylobacter spp infection; i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or afragment thereof which is capable of treating Campylobacter sppinfection; j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capabletreating Campylobacter spp infection; k) a peptide comprising the aminoacid sequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragment thereofwhich is capable of treating Campylobacter spp infection; 1) a peptidecomprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or afragment thereof which is capable of treating Campylobacter sppinfection; m) a peptide comprising the amino acid sequenceTGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which is capableof treating Campylobacter spp infection; n) a peptide comprising theamino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragmentthereof which is capable of treating Campylobacter spp infection, o) apeptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO:15) or a fragment thereof which is capable of treating Campylobacter sppinfection; p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragment thereof which is capableof treating Campylobacter spp infection; q) a peptide comprising theamino acid sequence VLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragmentthereof. which is capable of treating Campylobacter spp infection; r) apeptide comprising the amino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO:18) or a fragment thereof which is capable of treating Campylobacter sppinfection; s) a peptide comprising the amino acid sequenceVRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragment thereof which is capableof treating Campylobacter spp infection; t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20) or a fragmentthereof which is capable of treating Campylobacter spp infection; u) apeptide comprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO:21) or a fragment thereof which is capable of treating Campylobacter sppinfection; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof treating Campylobacter spp infection; w) a peptide comprising theamino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragmentthereof which is capable of treating Campylobacter spp infection; x) apeptide comprising the amino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO:24) or a fragment thereof which is capable of treating Campylobacter sppinfection; y) a peptide comprising the amino acid sequenceKALYALHVPSMQVFA (SEQ ID NO: 25) or a fragment thereof which is capableof treating Campylobacter spp infection; z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragmentthereof which is capable of treating Campylobacter spp infection; andaa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ IDNO: 27) or a fragment thereof which is capable of treating Campylobacterspp infection.

In another aspect, the present invention relates to use of one or morepeptides selected from the group consisting of:

a) a peptide comprising the amino acid sequence EGVLGAALSAFSFDS (SEQ IDNO: 1) or a fragment thereof which is capable of treating Campylobacterspp infection;b) a peptide comprising the amino acid sequence QAQPCPNQPDGSVYA (SEQ IDNO: 2) or a fragment thereof which is capable of treating Campylobacterspp infection;c) a peptide comprising the amino acid sequence STALPLWSNYSYDSA (SEQ IDNO: 3) or a fragment thereof which is capable of treating Campylobacterspp infection;d) a peptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ IDNO: 4) or a fragment thereof which is capable of treating Campylobacterspp infection;e) a peptide comprising the amino acid sequence KAIAFQSSPGSPVLL (SEQ IDNO: 5) or a fragment thereof which is capable of treating Campylobacterspp infection;f) a peptide comprising the amino acid sequence TCNLSDYTLPRARVL (SEQ IDNO: 6) or a fragment thereof which is capable of treating Campylobacterspp infection;g) a peptide comprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ IDNO: 7) or a fragment thereof which is capable of treating Campylobacterspp infection;h) a peptide comprising the amino acid sequence VPESIHKASLVCYRF (SEQ IDNO: 8) or a fragment thereof which is capable of treating Campylobacterspp infection;i) a peptide comprising the amino acid sequence SRPIARFYTWSQNTT (SEQ IDNO: 9) or a fragment thereof which is capable of treating Campylobacterspp infection;j) a peptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQ IDNO: 10) or a fragment thereof which is capable treating Campylobacterspp infection;k) a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ (SEQ IDNO: 11) or a fragment thereof which is capable of treating Campylobacterspp infection;l) a peptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ IDNO: 12) or a fragment thereof which is capable of treating Campylobacterspp infection;m) a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ IDNO: 13) or a fragment thereof which is capable of treating Campylobacterspp infection;n) a peptide comprising the amino acid sequence FLIDSPLASIGPTSM (SEQ IDNO: 14) or a fragment thereof which is capable of treating Campylobacterspp infection;o) a peptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQ IDNO: 15) or a fragment thereof which is capable of treating Campylobacterspp infection;p) a peptide comprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ IDNO: 16) or a fragment thereof which is capable of treating Campylobacterspp infection;q) a peptide comprising the amino acid sequence VLAWFSPLTLESSRL (SEQ IDNO: 17) or a fragment thereof which is capable of treating Campylobacterspp infection;r) a peptide comprising the amino acid sequence VIDLSGTRKSSSGTM (SEQ IDNO: 18) or a fragment thereof which is capable of treating Campylobacterspp infection;s) a peptide comprising the amino acid sequence VRKTTSHPPSYALLH (SEQ IDNO: 19) or a fragment thereof which is capable of treating Campylobacterspp infection;t) a peptide comprising the amino acid sequence TPPYRAALATPVLLL (SEQ IDNO: 20) or a fragment thereof which is capable of treating Campylobacterspp infection;u) a peptide comprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ IDNO: 21) or a fragment thereof which is capable of treating Campylobacterspp infection;v) a peptide comprising the amino acid sequence HRPVKTPANAPTTMM (SEQ IDNO: 22) or a fragment thereof which is capable of treating Campylobacterspp infection;w) a peptide comprising the amino acid sequence CFNDPLDIVPPMLLL (SEQ IDNO: 23) or a fragment thereof which is capable of treating Campylobacterspp infection;x) a peptide comprising the amino acid sequence AHAPCSLFFPLSLRP (SEQ IDNO: 24) or a fragment thereof which is capable of treating Campylobacterspp infection;y) a peptide comprising the amino acid sequence KALYALHVPSMQVFA (SEQ IDNO: 25) or a fragment thereof which is capable of treating Campylobacterspp infection;z) a peptide comprising the amino acid sequence RPSRWPWQEPLPISI (SEQ IDNO: 26) or a fragment thereof which is capable of treating Campylobacterspp infection; andaa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ IDNO: 27) or a fragment thereof which is capable of treating Campylobacterspp infection in the manufacture of a medicament for the treatment ofCampylobacter spp infection in a subject.

In another aspect, the present invention relates to a method ofdiagnosing a Campylobacter spp. infection in a subject comprising:

1) providing a sample from the subject;2) contacting the sample with one or more peptides under conditionswhich permit binding of the one or more peptides to Campylobacter sp.;and3) determining if the one or more peptides bind to a Campylobacter spp.in the sample, wherein the one or more peptides are selected from thegroup consisting of: a) a peptide comprising the amino acid sequenceEGVLGAALSAFSFDS (SEQ ID NO: 1) or a fragment thereof which is capable ofdiagnosing Campylobacter spp infection; b) a peptide comprising theamino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereofwhich is capable of diagnosing Campylobacter spp infection; c) a peptidecomprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or afragment thereof which is capable of diagnosing Campylobacter sppinfection; d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof which is capable ofdiagnosing Campylobacter spp infection; e) a peptide comprising theamino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereofwhich is capable of diagnosing Campylobacter spp infection; f) a peptidecomprising the amino acid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or afragment thereof which is capable of diagnosing Campylobacter sppinfection; g) a peptide comprising the amino acid sequenceNFLCPSPYPKVQPGL (SEQ ID NO: 7) or a fragment thereof which is capable ofdiagnosing Campylobacter spp infection; h) a peptide comprising theamino acid sequence VPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereofwhich is capable of diagnosing Campylobacter spp infection; i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or afragment thereof which is capable of diagnosing Campylobacter sppinfection; j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capablediagnosing Campylobacter spp infection; k) a peptide comprising theamino acid sequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; 1) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; m) a peptide comprising the amino acid sequenceTGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; n) a peptide comprising theamino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection, o) apeptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO:15) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; q) a peptide comprising theamino acid sequence VLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; r) apeptide comprising the amino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO:18) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; s) a peptide comprising the amino acid sequenceVRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; u) apeptide comprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO:21) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; w) a peptide comprising theamino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; x) apeptide comprising the amino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO:24) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; y) a peptide comprising the amino acid sequenceKALYALHVPSMQVFA (SEQ ID NO: 25) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; andaa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ IDNO: 27) or a fragment thereof which is capable of diagnosingCampylobacter spp infection.

In one embodiment, the one or more peptides bind to the Campylobacterspp. to prevent, treat or diagnose Campylobacter spp. infection. The oneor more peptides may bind specifically to the Campylobacter species toprevent, treat or diagnose Campylobacter spp. infection.

The Campylobacter spp. may be any species of Campylobacter. In oneembodiment, the Campylobacter spp. is Campylobacter jejuni. In anotherembodiment, the Campylobacter spp. is selected from the group consistingof Campylobacter coli, C. lari, C. Upsaliensis, C. concisus, C. curvus,C. fetus, C. graciius, C. helveticus, C. hyoilei, C. hyointestinalis, C.lanienae, C. mucosalis, C. rectus, C. showae, and C. sputorum.

The subject may be human. The subject may be poultry, such as a chicken,duck, goose or turkey. The subject may be a domesticated animal, forexample a cat or dog, or an agricultural animal, for example a pig, cowor sheep.

In one embodiment, the one or more peptides is a peptide comprising theamino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1), or a fragmentthereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence QAQPCPNQPDGSVYA (SEQ IDNO: 2) or a fragment thereof which is capable of preventing, treating ordiagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceSTALPLWSNYSYDSA (SEQ ID NO: 3) or a fragment thereof which is capable ofpreventing, treating or diagnosing Campylobacter spp infection. In oneembodiment, the one or more peptides is a peptide comprising the aminoacid sequence RTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof whichis capable of preventing, treating or diagnosing Campylobacter sppinfection. In one embodiment, the one or more peptides is a peptidecomprising the amino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or afragment thereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence TCNLSDYTLPRARVL (SEQ IDNO: 6) or a fragment thereof which is capable of preventing, treating ordiagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceNFLCPSPYPKVQPGL (SEQ ID NO: 7) or a fragment thereof which is capable ofpreventing, treating or diagnosing Campylobacter spp infection. In oneembodiment, the one or more peptides is a peptide comprising the aminoacid sequence VPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof whichis capable of preventing, treating or diagnosing Campylobacter sppinfection. In one embodiment, the one or more peptides is a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or afragment thereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQ IDNO: 10) or a fragment thereof which is capable of preventing, treatingor diagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceLPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragment thereof which is capableof preventing, treating or diagnosing Campylobacter spp infection. Inone embodiment, the one or more peptides is a peptide comprising theamino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragmentthereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ IDNO: 13) or a fragment thereof which is capable of preventing, treatingor diagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragment thereof which is capableof preventing, treating or diagnosing Campylobacter spp infection. Inone embodiment, the one or more peptides is a peptide comprising theamino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15) or a fragmentthereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ IDNO: 16), or a fragment thereof which is capable of preventing, treatingor diagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceVLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragment thereof which is capableof preventing, treating or diagnosing Campylobacter spp infection. Inone embodiment, the one or more peptides is a peptide comprising theamino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragmentthereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence VRKTTSHPPSYALLH (SEQ IDNO: 19) or a fragment thereof which is capable of preventing, treatingor diagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceTPPYRAALATPVLLL (SEQ ID NO: 20) or a fragment thereof which is capableof preventing, treating or diagnosing Campylobacter spp infection. Inone embodiment, the one or more peptides is a peptide comprising theamino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21) or a fragmentthereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence HRPVKTPANAPTTMM (SEQ IDNO: 22) or a fragment thereof which is capable of preventing, treatingor diagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceCFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragment thereof which is capableof preventing, treating or diagnosing Campylobacter spp infection. Inone embodiment, the one or more peptides is a peptide comprising theamino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragmentthereof which is capable of preventing, treating or diagnosingCampylobacter spp infection. In one embodiment, the one or more peptidesis a peptide comprising the amino acid sequence KALYALHVPSMQVFA (SEQ IDNO: 25) or a fragment thereof which is capable of preventing, treatingor diagnosing Campylobacter spp infection. In one embodiment, the one ormore peptides is a peptide comprising the amino acid sequenceRPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragment thereof which is capableof preventing, treating or diagnosing Campylobacter spp infection. Inone embodiment, the one or more peptides is a peptide comprising theamino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27) or a fragmentthereof which is capable of preventing, treating or diagnosingCampylobacter spp infection.

In another aspect, the present invention relates to an isolated peptidecomprising an amino acid sequence selected from the group consisting of:

EGVLGAALSAFSFDS; (SEQ ID NO: 1) QAQPCPNQPDGSVYA; (SEQ ID NO: 2)STALPLWSNYSYDSA; (SEQ ID NO: 3) RTFGAKPPNIPFPRR; (SEQ ID NO: 4)KAIAFQSSPGSPVLL; (SEQ ID NO: 5) TCNLSDYTLPRARVL; (SEQ ID NO: 6)NFLCPSPYPKVQPGL; (SEQ ID NO: 7) VPESIHKASLVCYRF; (SEQ ID NO: 8)SRPIARFYTWSQNTT; (SEQ ID NO: 9) FSPFRISELVYTLHP; (SEQ ID NO: 10)LPFNLAKPELYIFVQ; (SEQ ID NO: 11) GRFLIRVTSSPLGPD; (SEQ ID NO: 12)TGSGLYLHQMVYLYQ; (SEQ ID NO: 13) FLIDSPLASIGPTSM, (SEQ ID NO: 14)FMIDSPLASIGPTSM; (SEQ ID NO: 15) FLSDPPAPPTSPGVV; (SEQ ID NO: 16)VLAWFSPLTLESSRL; (SEQ ID NO: 17) VIDLSGTRKSSSGTM; (SEQ ID NO: 18)VRKTTSHPPSYALLH; (SEQ ID NO: 19) TPPYRAALATPVLLL; (SEQ ID NO: 20)LSAPSPMFLPPVNPH; (SEQ ID NO: 21) HRPVKTPANAPTTMM; (SEQ ID NO: 22)CFNDPLDIVPPMLLL; (SEQ ID NO: 23) AHAPCSLFFPLSLRP; (SEQ ID NO: 24)KALYALHVPSMQVFA; (SEQ ID NO: 25) RPSRWPWQEPLPISI; (SEQ ID NO: 26) andKVQIIPKDTLAPLPP. (SEQ ID NO: 27)

In another aspect, the present invention relates to an isolated peptideof 15 to 100 amino acid residues comprising an amino acid sequenceselected from the group consisting of: EGVLGAALSAFSFDS (SEQ ID NO: 1);QAQPCPNQPDGSVYA (SEQ ID NO: 2); STALPLWSNYSYDSA (SEQ ID NO: 3);RTFGAKPPNIPFPRR (SEQ ID NO: 4); KAIAFQSSPGSPVLL (SEQ ID NO: 5);TCNLSDYTLPRARVL (SEQ ID NO: 6); NFLCPSPYPKVQPGL (SEQ ID NO: 7);VPESIHKASLVCYRF (SEQ ID NO: 8); SRPIARFYTWSQNTT (SEQ ID NO: 9);FSPFRISELVYTLHP (SEQ ID NO: 10); LPFNLAKPELYIFVQ (SEQ ID NO: 11);GRFLIRVTSSPLGPD (SEQ ID NO: 12); TGSGLYLHQMVYLYQ (SEQ ID NO: 13);FLIDSPLASIGPTSM (SEQ ID NO: 14), FMIDSPLASIGPTSM (SEQ ID NO: 15);FLSDPPAPPTSPGVV (SEQ ID NO: 16); VLAWFSPLTLESSRL (SEQ ID NO: 17);VIDLSGTRKSSSGTM (SEQ ID NO: 18); VRKTTSHPPSYALLH (SEQ ID NO: 19);TPPYRAALATPVLLL (SEQ ID NO: 20); LSAPSPMFLPPVNPH (SEQ ID NO: 21);HRPVKTPANAPTTMM (SEQ ID NO: 22); CFNDPLDIVPPMLLL (SEQ ID NO: 23);AHAPCSLFFPLSLRP (SEQ ID NO: 24); KALYALHVPSMQVFA (SEQ ID NO: 25);RPSRWPWQEPLPISI (SEQ ID NO: 26); and KVQIIPKDTLAPLPP (SEQ ID NO: 27).

In another aspect, the present invention relates to a synthetic peptidecomprising an amino acid sequence selected from the group consisting of:

EGVLGAALSAFSFDS; (SEQ ID NO: 1) QAQPCPNQPDGSVYA; (SEQ ID NO: 2)STALPLWSNYSYDSA; (SEQ ID NO: 3) RTFGAKPPNIPFPRR; (SEQ ID NO: 4)KAIAFQSSPGSPVLL; (SEQ ID NO: 5) TCNLSDYTLPRARVL; (SEQ ID NO: 6)NFLCPSPYPKVQPGL; (SEQ ID NO: 7) VPESIHKASLVCYRF; (SEQ ID NO: 8)SRPIARFYTWSQNTT; (SEQ ID NO: 9) FSPFRISELVYTLHP; (SEQ ID NO: 10)LPFNLAKPELYIFVQ; (SEQ ID NO: 11) GRFLIRVTSSPLGPD; (SEQ ID NO: 12)TGSGLYLHQMVYLYQ; (SEQ ID NO: 13) FLIDSPLASIGPTSM, (SEQ ID NO: 14)FMIDSPLASIGPTSM; (SEQ ID NO: 15) FLSDPPAPPTSPGVV; (SEQ ID NO: 16)VLAWFSPLTLESSRL; (SEQ ID NO: 17) VIDLSGTRKSSSGTM; (SEQ ID NO: 18)VRKTTSHPPSYALLH; (SEQ ID NO: 19) TPPYRAALATPVLLL; (SEQ ID NO: 20)LSAPSPMFLPPVNPH; (SEQ ID NO: 21) HRPVKTPANAPTTMM; (SEQ ID NO: 22)CFNDPLDIVPPMLLL; (SEQ ID NO: 23) AHAPCSLFFPLSLRP; (SEQ ID NO: 24)KALYALHVPSMQVFA; (SEQ ID NO: 25) RPSRWPWQEPLPISI; (SEQ ID NO: 26) andKVQIIPKDTLAPLPP. (SEQ ID NO: 27)

In another aspect, the present invention relates to a fusion proteincomprising one or more peptides, wherein the one or more peptides areselected from the group consisting of: EGVLGAALSAFSFDS (SEQ ID NO: 1);QAQPCPNQPDGSVYA (SEQ ID NO: 2); STALPLWSNYSYDSA (SEQ ID NO: 3);RTFGAKPPNIPFPRR (SEQ ID NO: 4); KAIAFQSSPGSPVLL (SEQ ID NO: 5);TCNLSDYTLPRARVL (SEQ ID NO: 6); NFLCPSPYPKVQPGL (SEQ ID NO: 7);VPESIHKASLVCYRF (SEQ ID NO: 8); SRPIARFYTWSQNTT (SEQ ID NO: 9);FSPFRISELVYTLHP (SEQ ID NO: 10); LPFNLAKPELYIFVQ (SEQ ID NO: 11);GRFLIRVTSSPLGPD (SEQ ID NO: 12); TGSGLYLHQMVYLYQ (SEQ ID NO: 13);FLIDSPLASIGPTSM (SEQ ID NO: 14), FMIDSPLASIGPTSM (SEQ ID NO: 15);FLSDPPAPPTSPGVV (SEQ ID NO: 16); VLAWFSPLTLESSRL (SEQ ID NO: 17);VIDLSGTRKSSSGTM (SEQ ID NO: 18); VRKTTSHPPSYALLH (SEQ ID NO: 19);TPPYRAALATPVLLL (SEQ ID NO: 20); LSAPSPMFLPPVNPH (SEQ ID NO: 21);HRPVKTPANAPTTMM (SEQ ID NO: 22); CFNDPLDIVPPMLLL (SEQ ID NO: 23);AHAPCSLFFPLSLRP (SEQ ID NO: 24); KALYALHVPSMQVFA (SEQ ID NO: 25);RPSRWPWQEPLPISI (SEQ ID NO: 26); and KVQIIPKDTLAPLPP (SEQ ID NO: 27).

In one embodiment, the fusion protein further comprises a phage coat orpart thereof.

In another aspect, the present invention relates to fd-tet phagecomprising one or more peptides, wherein the one or more peptides areselected from the group consisting of: EGVLGAALSAFSFDS (SEQ ID NO: 1);QAQPCPNQPDGSVYA (SEQ ID NO: 2); STALPLWSNYSYDSA (SEQ ID NO: 3);RTFGAKPPNIPFPRR (SEQ ID NO: 4); KAIAFQSSPGSPVLL (SEQ ID NO: 5);TCNLSDYTLPRARVL (SEQ ID NO: 6); NFLCPSPYPKVQPGL (SEQ ID NO: 7);VPESIHKASLVCYRF (SEQ ID NO: 8); SRPIARFYTWSQNTT (SEQ ID NO: 9);FSPFRISELVYTLHP (SEQ ID NO: 10); LPFNLAKPELYIFVQ (SEQ ID NO: 11);GRFLIRVTSSPLGPD (SEQ ID NO: 12); TGSGLYLHQMVYLYQ (SEQ ID NO: 13);FLIDSPLASIGPTSM (SEQ ID NO: 14), FMIDSPLASIGPTSM (SEQ ID NO: 15);FLSDPPAPPTSPGVV (SEQ ID NO: 16); VLAWFSPLTLESSRL (SEQ ID NO: 17);VIDLSGTRKSSSGTM (SEQ ID NO: 18); VRKTTSHPPSYALLH (SEQ ID NO: 19);TPPYRAALATPVLLL (SEQ ID NO: 20); LSAPSPMFLPPVNPH (SEQ ID NO: 21);HRPVKTPANAPTTMM (SEQ ID NO: 22); CFNDPLDIVPPMLLL (SEQ ID NO: 23);AHAPCSLFFPLSLRP (SEQ ID NO: 24); KALYALHVPSMQVFA (SEQ ID NO: 25);RPSRWPWQEPLPISI (SEQ ID NO: 26); and KVQIIPKDTLAPLPP (SEQ ID NO: 27).

In another aspect, the present invention relates to a compositioncomprising one or more peptides, wherein the one of more peptides areselected from the group consisting of: a) a peptide comprising the aminoacid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1); b) a peptide comprisingthe amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2); c) a peptidecomprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3); d) apeptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO:4); e) a peptide comprising the amino acid sequence KAIAFQSSPGSPVLL (SEQID NO: 5); f) a peptide comprising the amino acid sequenceTCNLSDYTLPRARVL (SEQ ID NO: 6); g) a peptide comprising the amino acidsequence NFLCPSPYPKVQPGL (SEQ ID NO: 7); h) a peptide comprising theamino acid sequence VPESIHKASLVCYRF (SEQ ID NO: 8); i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9); j) apeptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO:10); k) a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ(SEQ ID NO: 11); 1) a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12; m) a peptide comprising the amino acidsequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13); n) a peptide comprising theamino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14), o) a peptidecomprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15); p) apeptide comprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO:16); q) a peptide comprising the amino acid sequence VLAWFSPLTLESSRL(SEQ ID NO: 17); r) a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18); s) a peptide comprising the amino acidsequence VRKTTSHPPSYALLH (SEQ ID NO: 19); t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20); u) a peptidecomprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21); v) apeptide comprising the amino acid sequence HRPVKTPANAPTTMM (SEQ ID NO:22); w) a peptide comprising the amino acid sequence CFNDPLDIVPPMLLL(SEQ ID NO: 23); x) a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24); y) a peptide comprising the amino acidsequence KALYALHVPSMQVFA (SEQ ID NO: 25); z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26); and aa) a peptidecomprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27).

In another aspect, the present invention relates to a pharmaceuticalcomposition comprising one or more peptides and a pharmaceuticallyacceptable carrier, wherein the one of more peptides are selected fromthe group consisting of: a) a peptide comprising the amino acid sequenceEGVLGAALSAFSFDS (SEQ ID NO: 1); b) a peptide comprising the amino acidsequence QAQPCPNQPDGSVYA (SEQ ID NO: 2); c) a peptide comprising theamino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3);

d) a peptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ IDNO: 4); e) a peptide comprising the amino acid sequence KAIAFQSSPGSPVLL(SEQ ID NO: 5); f) a peptide comprising the amino acid sequenceTCNLSDYTLPRARVL (SEQ ID NO: 6); g) a peptide comprising the amino acidsequence NFLCPSPYPKVQPGL (SEQ ID NO: 7); h) a peptide comprising theamino acid sequence VPESIHKASLVCYRF (SEQ ID NO: 8); i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9); j) apeptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO:10); k) a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ(SEQ ID NO: 11); 1) a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12; m) a peptide comprising the amino acidsequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13); n) a peptide comprising theamino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14), o) a peptidecomprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15); p) apeptide comprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO:16); q) a peptide comprising the amino acid sequence VLAWFSPLTLESSRL(SEQ ID NO: 17); r) a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18); s) a peptide comprising the amino acidsequence VRKTTSHPPSYALLH (SEQ ID NO: 19); t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20); u) a peptidecomprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21); v) apeptide comprising the amino acid sequence HRPVKTPANAPTTMM (SEQ ID NO:22); w) a peptide comprising the amino acid sequence CFNDPLDIVPPMLLL(SEQ ID NO: 23); x) a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24); y) a peptide comprising the amino acidsequence KALYALHVPSMQVFA (SEQ ID NO: 25); z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26); and aa) a peptidecomprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27).

In another aspect, the present invention relates to an isolated nucleicacid molecule which encodes a peptide selected from the group consistingof: a) a peptide comprising the amino acid sequence EGVLGAALSAFSFDS (SEQID NO: 1); b) a peptide comprising the amino acid sequenceQAQPCPNQPDGSVYA (SEQ ID NO: 2); c) a peptide comprising the amino acidsequence STALPLWSNYSYDSA (SEQ ID NO: 3); d) a peptide comprising theamino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO: 4); e) a peptidecomprising the amino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5); f) apeptide comprising the amino acid sequence TCNLSDYTLPRARVL (SEQ ID NO:6); g) a peptide comprising the amino acid sequence NFLCPSPYPKVQPGL (SEQID NO: 7); h) a peptide comprising the amino acid sequenceVPESIHKASLVCYRF (SEQ ID NO: 8); i) a peptide comprising the amino acidsequence SRPIARFYTWSQNTT (SEQ ID NO: 9); j) a peptide comprising theamino acid sequence FSPFRISELVYTLHP (SEQ ID NO: 10); k) a peptidecomprising the amino acid sequence LPFNLAKPELYIFVQ (SEQ ID NO: 11); 1) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12); m) a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ(SEQ ID NO: 13); n) a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14), o) a peptide comprising the amino acidsequence FMIDSPLASIGPTSM (SEQ ID NO: 15); p) a peptide comprising theamino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16); q) a peptidecomprising the amino acid sequence VLAWFSPLTLESSRL (SEQ ID NO: 17); r) apeptide comprising the amino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO:18); s) a peptide comprising the amino acid sequence VRKTTSHPPSYALLH(SEQ ID NO: 19); t) a peptide comprising the amino acid sequenceTPPYRAALATPVLLL (SEQ ID NO: 20); u) a peptide comprising the amino acidsequence LSAPSPMFLPPVNPH (SEQ ID NO: 21); v) a peptide comprising theamino acid sequence HRPVKTPANAPTTMM (SEQ ID NO: 22); w) a peptidecomprising the amino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23); x) apeptide comprising the amino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO:24); y) a peptide comprising the amino acid sequence KALYALHVPSMQVFA(SEQ ID NO: 25); z) a peptide comprising the amino acid sequenceRPSRWPWQEPLPISI (SEQ ID NO: 26); and aa) a peptide comprising the aminoacid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27).

In another aspect, the present invention relates to a recombinant vectorcomprising an isolated nucleic acid molecule which encodes a peptideselected from the group consisting of: a) a peptide comprising the aminoacid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1); b) a peptide comprisingthe amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2); c) a peptidecomprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3); d) apeptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO:4); e) a peptide comprising the amino acid sequence KAIAFQSSPGSPVLL (SEQID NO: 5); f) a peptide comprising the amino acid sequenceTCNLSDYTLPRARVL (SEQ ID NO: 6); g) a peptide comprising the amino acidsequence NFLCPSPYPKVQPGL (SEQ ID NO: 7); h) a peptide comprising theamino acid sequence VPESIHKASLVCYRF (SEQ ID NO: 8); i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9); j) apeptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO:10); k) a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ(SEQ ID NO: 11); 1) a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12); m) a peptide comprising the amino acidsequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13); n) a peptide comprising theamino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14), o) a peptidecomprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15); p) apeptide comprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO:16); q) a peptide comprising the amino acid sequence VLAWFSPLTLESSRL(SEQ ID NO: 17); r) a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18); s) a peptide comprising the amino acidsequence VRKTTSHPPSYALLH (SEQ ID NO: 19); t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20); u) a peptidecomprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21); v) apeptide comprising the amino acid sequence HRPVKTPANAPTTMM (SEQ ID NO:22); w) a peptide comprising the amino acid sequence CFNDPLDIVPPMLLL(SEQ ID NO: 23); x) a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24); y) a peptide comprising the amino acidsequence KALYALHVPSMQVFA (SEQ ID NO: 25); z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26); and aa) a peptidecomprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27).

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates a selection strategy for isolating phage peptideswhich bind to C. jejuni.

-   -   A. Phage peptides from an f88-4/15-mer library were directly        selected against C. jejuni strain ACM 3393, resulting in “AP”        and “AT” pools of phage peptides.    -   B. A phage-display library was subtracted once against C. jejuni        strain ACM 3393 (black box), prior to three rounds of affinity        selection against C. jejuni strain ACM 3393. This resulted in        “BP” and “BT” phage peptides.    -   C. A phage-display library was subtracted twice against C.        jejuni strain ACM 3393, prior to three rounds of affinity        selection against C. jejuni strain C338 (poultry strain). This        resulted in “CP” and “CT” phage peptides.    -   D. A phage-display library was subtracted twice against C.        jejuni strain ACM 3393 and once against C. jejuni strain C338,        prior to three rounds of affinity selection against C338. This        resulted in “DP” and “DT” phage peptides.

FIG. 2 illustrates the different morphologies of C. jejuni strain C338when incubated with selected phage-displayed peptides.

-   -   A. Strain C338 incubated with phage peptide CP3/1. The        morphology has changed to thread-shaped.    -   B. Strain C338 incubated with unselected phage library showing        the normal spiral-shaped morphology    -   C. Strain C338 incubated with BP3/5 showing coccoid shaped        bacteria

FIG. 3 illustrates the amino acid alignment of AT3/5 with relatedproteins. The amino acid sequences deduced from AT3/5, Oryctolaguscuniculus claudin 1 (Rabbit; Accession No. ABK59974), Homo sapiensclaudin 1 (Accession No. AAP97236) and Macaca mulatta (Rhesus monkey;Accession No. XP_(—)001093143) were aligned using ClustalW. GeneDoc wasused as the shading editor. The shading levels used to indicate degreeof conservation in each column was black for 100% conservation and greyfor 75% amino acid conservation. Note that the first 120 amino acids ofthe amino acid alignment are presented.

FIG. 4 illustrates the amino acid alignment of BT3/3 with C. jejuniflagella hook length control proteins.

The amino acid sequences deduced from BT3/3, C. jejuni subsp. doyleiiflgE gene (Accession No. EAU02210), C. jejuni isolate 5226 (AccessionNo. AAP34261), C. jejuni subsp. jejuni 81-176 (Accession No. CAA12127)and C. jejuni strain NCTC11168 were aligned using ClustalW with GeneDocused as the shading editor.

DETAILED DESCRIPTION OF THE INVENTION 1. Peptides

The present invention relates to isolated peptides which bind toCampylobacter spp and typically inhibit growth of or kill Campylobacterspp. The peptides are selected from the group consisting of a) a peptidecomprising the amino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1); b) apeptide comprising the amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO:2); c) a peptide comprising the amino acid sequence STALPLWSNYSYDSA (SEQID NO: 3); d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4); e) a peptide comprising the amino acidsequence KAIAFQSSPGSPVLL (SEQ ID NO: 5); f) a peptide comprising theamino acid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6); g) a peptidecomprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7); h) apeptide comprising the amino acid sequence VPESIHKASLVCYRF (SEQ ID NO:8); i) a peptide comprising the amino acid sequence SRPIARFYTWSQNTT (SEQID NO: 9); j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10); k) a peptide comprising the amino acidsequence LPFNLAKPELYIFVQ (SEQ ID NO: 11); 1) a peptide comprising theamino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12; m) a peptidecomprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13); n) apeptide comprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO:14), o) a peptide comprising the amino acid sequence FMIDSPLASIGPTSM(SEQ ID NO: 15); p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16); q) a peptide comprising the amino acidsequence VLAWFSPLTLESSRL (SEQ ID NO: 17); r) a peptide comprising theamino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO: 18); s) a peptidecomprising the amino acid sequence VRKTTSHPPSYALLH (SEQ ID NO: 19); t) apeptide comprising the amino acid sequence TPPYRAALATPVLLL (SEQ ID NO:20); u) a peptide comprising the amino acid sequence LSAPSPMFLPPVNPH(SEQ ID NO: 21); v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22); w) a peptide comprising the amino acidsequence CFNDPLDIVPPMLLL (SEQ ID NO: 23); x) a peptide comprising theamino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO: 24); y) a peptidecomprising the amino acid sequence KALYALHVPSMQVFA (SEQ ID NO: 25); z) apeptide comprising the amino acid sequence RPSRWPWQEPLPISI (SEQ ID NO:26); and aa) a peptide comprising the amino acid sequenceKVQIIPKDTLAPLPP (SEQ ID NO: 27).

As described herein peptides which bind to Campylobacter jejuni wereisolated from a phage-display library consisting of filamentous fd-tetphage displaying random 15-mer peptides fused to 150-300 copies of majorcoat protein pVIII (Scott & Smith, 1990) and contained a complexity of2×10⁹ peptidevariants/mL [supplied by Dr. George Smith (University ofMissouri-Columbia, USA)].

The peptides of the invention may be produced by recombinant methods, ormay be chemically synthesized. Methods for producing recombinantpeptides are known in the art and are described in, for example, Zwicket al. 1998. Methods of chemical synthesis of the peptides are known inthe art and are described in, for example, they may be prepared bysolid-phase synthesis as described by Stewart et al, 1984.

As described herein, the peptides of the invention bind to C. jejunistrain ACM 3393. The inventors envisage that the peptides of theinvention will bind to Campylobacter spp. The peptides may exhibitpreferential binding to Campylobacter spp. The peptides may bindspecifically to Campylobacter spp.

The present invention also relates to fragments of the abovementionedpeptides which are capable of binding to Campylobacter spp. The methodsemployed to produce the peptides described herein may also be used toproduce fragments of the peptides which bind to Campylobacter spp.

Functional variants of the abovementioned peptides which may be capableof binding to Campylobacter spp. are also within the scope of theinvention. Methods of producing functional variants of peptides areknown in the art. Also encompassed in the invention are isolatedpeptides of 15 to about 100 amino acid residues comprising theabovementioned peptides. Examples of the peptides includes a peptidebetween 15 and 75 amino acid residues in length, a peptide between 15and 50 amino acid residues in length, a peptide between 15 and 25 aminoacid residues in length.

The peptides and fragments thereof may be tested against strains ofCampylobacter spp as described herein for their binding ability toCampylobacter spp and/or their ability to inhibit growth of or killCampylobacter spp.

2. Methods of Inhibiting Growth of or Killing Campylobacter spp

The inventors have found that peptides which bind to Campylobacterjejuni may be suitable for inhibiting growth of or killing Campylobacterspp. Accordingly, the present invention further relates to methods ofinhibiting growth of or killing Campylobacter spp using one or morepeptides selected from the group consisting of a) a peptide comprisingthe amino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1); b) a peptidecomprising the amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2); c) apeptide comprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO:3); d) a peptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQID NO: 4); e) a peptide comprising the amino acid sequenceKAIAFQSSPGSPVLL (SEQ ID NO: 5); f) a peptide comprising the amino acidsequence TCNLSDYTLPRARVL (SEQ ID NO: 6); g) a peptide comprising theamino acid sequence FLCPSPYPKVQPGL (SEQ ID NO: 7); h) a peptidecomprising the amino acid sequence VPESIHKASLVCYRF (SEQ ID NO: 8); i) apeptide comprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO:9); j) a peptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQID NO: 10); k) a peptide comprising the amino acid sequenceLPFNLAKPELYIFVQ (SEQ ID NO: 11); 1) a peptide comprising the amino acidsequence GRFLIRVTSSPLGPD (SEQ ID NO: 12; m) a peptide comprising theamino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13); n) a peptidecomprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14); o) apeptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO:15); p) a peptide comprising the amino acid sequence FLSDPPAPPTSPGVV(SEQ ID NO: 16); q) a peptide comprising the amino acid sequenceVLAWFSPLTLESSRL (SEQ ID NO: 17); r) a peptide comprising the amino acidsequence VIDLSGTRKSSSGTM (SEQ ID NO: 18); s) a peptide comprising theamino acid sequence VRKTTSHPPSYALLH (SEQ ID NO: 19); t) a peptidecomprising the amino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20); u) apeptide comprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO:21); v) a peptide comprising the amino acid sequence HRPVKTPANAPTTMM(SEQ ID NO: 22); w) a peptide comprising the amino acid sequenceCFNDPLDIVPPMLLL (SEQ ID NO: 23); x) a peptide comprising the amino acidsequence AHAPCSLFFPLSLRP (SEQ ID NO: 24); y) a peptide comprising theamino acid sequence KALYALHVPSMQVFA (SEQ ID NO: 25); z) a peptidecomprising the amino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26); andaa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ IDNO: 27) or fragments thereof which are capable of inhibiting growth ofor killing Campylobacter spp.

In one embodiment, the method of inhibiting growth of or killingCampylobacter spp. comprises contacting the Campylobacter spp, with oneor more peptides selected from the group consisting of a) a peptidecomprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO: 10); b) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12); c) a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ(SEQ ID NO: 13); d) a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14) or e) a peptide comprising the aminoacid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16) or fragments of the one ormore peptides which are capable of inhibiting growth of or killingCampylobacter spp.

In another embodiment, the method of inhibiting growth of or killingCampylobacter spp. comprises contacting the Campylobacter spp. with oneor more peptides selected from the group consisting of a) a peptidecomprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12; b) apeptide comprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO:13) or c) a peptide comprising the amino acid sequence FLIDSPLASIGPTSM(SEQ ID NO: 14).

The methods of inhibiting growth of or killing Campylobacter spp. maycomprise contacting the Campylobacter spp. with only one ofabovementioned peptides or more than one of the abovementioned peptidesas a combination.

In one embodiment, the one or more peptides bind to the Campylobacterspp. to inhibit growth of or kill the Campylobacter spp. The one or morepeptides may bind preferentially to Campylobacter spp. to inhibitgrowth. The one or more peptides may bind specifically to Campylobacterspp. to inhibit growth.

The one or more peptides may be bactericidal. The one or more peptidesmay be bacteriostatic. The growth of Campylobacter spp may be inhibitedby preventing growth of the Campylobacter spp. The growth ofCampylobacter spp. may be inhibited by reducing or decreasing the growthrate of Campylobacter spp.

Growth of the Campylobacter spp. is inhibited by contacting theCampylobacter spp. with the one or more peptides. The Campylobacter spp.may be contacted with the peptide in any manner which inhibits thegrowth of Campylobacter spp. In one embodiment, the Campylobacter spp.is contacted with the peptide by incubating a culture of Campylobacterspp. with the one or more peptides.

The Campylobacter spp. may be killed by contacting the Campylobacterspp. with the one or more peptides. The Campylobacter spp. may becontacted with the peptide in any manner which kills the Campylobacterspp. In one embodiment, the Campylobacter spp. is contacted with thepeptide by incubating a culture of Campylobacter spp. with the one ormore peptides.

In one embodiment, the method of inhibiting growth may compriseinhibiting growth of or killing the Campylobacter spp. in a solution. Inanother embodiment, the method of inhibiting growth may compriseinhibiting growth of or killing the Campylobacter spp. on a surface.

The species of Campylobacter may be any species of Campylobacter inwhich the growth rate of the Campylobacter is reduced in the presence ofthe peptide relative to the growth rate of the Campylobacter in theabsence of the peptide or which is killed by the peptide. The methodsfor determining the ability of a peptide to inhibit growth of or killCampylobacter spp are described herein and are well within thecapabilities of the person skilled in the art.

Campylobacter spp includes C. jejuni, C. coli, C. lari, C. Upsaliensis,C. concisus, C. curvus, C. fetus, C. graciius, C. helveticus, C.hyoilei, C. hyointestinalis, C. lanienae, C. mucosalis, C. rectus, C.showae, and C. sputorum.

3. Methods of Treating or Preventing Campylobacter Infection

As described above, the inventors have found that peptides describedherein are capable of inhibiting growth of or killing Campylobacter spp.The inventors have also found that some peptides described herein showsimilarity to claudin 1 from animals such as Homo sapiens (Accession No.AAD22962); Rabbit (Oryctolagus cuniculus; Accession No.NP_(—)001082785); Rhesus monkey (Macaca mulatta; Accession No.XP_(—)001093143) and a flagella hook length control protein (flgE) fromC. jejuni [Accession No's YP_(—)001001371; EAQ71955; NP_(—)281265;AAP34261) as described by: Hendrixson & DiRita. 2003. The inventors havealso found that when some peptides described herein are contacted withC. jejuni, there is an effect on the morphology of the C. jejuni.Without wishing to be bound by theory, the inventors envisage that suchpeptides may inhibit the colonisation and invasion of thegastrointestinal cells of Campylobacter spp. The inventors thereforeenvisage that the peptides described herein can be used in the treatmentor prevention of Campylobacter spp infections.

Accordingly, the invention further relates to a method of treating orpreventing a Campylobacter spp infection in a subject comprisingadministering to the subject one or more peptides selected from thegroup consisting of: a) a peptide comprising the amino acid sequenceEGVLGAALSAFSFDS (SEQ ID NO: 1) or a fragment thereof which is capable oftreating or preventing Campylobacter spp infection; b) a peptidecomprising the amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or afragment thereof which is capable of treating or preventingCampylobacter spp infection; c) a peptide comprising the amino acidsequence STALPLWSNYSYDSA (SEQ ID NO: 3) or a fragment thereof which iscapable of treating or preventing Campylobacter spp infection; d) apeptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO:4) or a fragment thereof which is capable of treating or preventingCampylobacter spp infection; e) a peptide comprising the amino acidsequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereof which iscapable of treating or preventing Campylobacter spp infection; f) apeptide comprising the amino acid sequence TCNLSDYTLPRARVL (SEQ ID NO:6) or a fragment thereof which is capable of treating or preventingCampylobacter spp infection; g) a peptide comprising the amino acidsequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or a fragment thereof which iscapable of treating or preventing Campylobacter spp infection; h) apeptide comprising the amino acid sequence VPESIHKASLVCYRF (SEQ ID NO:8) or a fragment thereof which is capable of treating or preventingCampylobacter spp infection; i) a peptide comprising the amino acidsequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or a fragment thereof which iscapable of treating or preventing Campylobacter spp infection; j) apeptide comprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO:10) or a fragment thereof which is capable treating or preventingCampylobacter spp infection; k) a peptide comprising the amino acidsequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragment thereof which iscapable of treating or preventing Campylobacter spp infection; 1) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12) or a fragment thereof which is capable of treating or preventingCampylobacter spp infection; m) a peptide comprising the amino acidsequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which iscapable of treating or preventing Campylobacter spp infection; n) apeptide comprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO:14) or a fragment thereof which is capable of treating or preventingCampylobacter spp infection, o) a peptide comprising the amino acidsequence FMIDSPLASIGPTSM (SEQ ID NO: 15) or a fragment thereof which iscapable of treating or preventing Campylobacter spp infection; p) apeptide comprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO:16) or a fragment thereof which is capable of treating or preventingCampylobacter spp; q) a peptide comprising the amino acid sequenceVLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragment thereof which is capableof treating or preventing treating or preventing Campylobacter spp; r) apeptide comprising the amino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO:18) or a fragment thereof which is capable of treating or preventingCampylobacter spp; s) a peptide comprising the amino acid sequenceVRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragment thereof which is capableof treating or preventing Campylobacter spp; t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20) or a fragmentthereof which is capable of treating or preventing Campylobacter spp; u)a peptide comprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO:21) or a fragment thereof which is capable of treating or preventingCampylobacter spp; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof treating or preventing Campylobacter spp; w) a peptide comprising theamino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragmentthereof which is capable of treating or preventing Campylobacter spp; x)a peptide comprising the amino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO:24) or a fragment thereof which is capable of treating or preventingCampylobacter spp; y) a peptide comprising the amino acid sequenceKALYALHVPSMQVFA (SEQ ID NO: 25) or a fragment thereof which is capableof treating or preventing Campylobacter spp; z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragmentthereof which is capable of treating or preventing Campylobacter spp;and aa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP(SEQ ID NO: 27) or a fragment thereof which is capable of treating orpreventing Campylobacter spp.

In one embodiment, the method of treating or preventing a Campylobacterspp infection in a subject comprises administering to the subject one ormore peptides selected from the group consisting of: a) a peptidecomprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO: 10); b) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12; c) a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQID NO: 13); d) a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14) or e) a peptide comprising the aminoacid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16)

In another embodiment, the method of treating or preventing aCampylobacter spp infection in a subject comprises administering to thesubject one or more peptides selected from the group consisting of: a) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12; b) a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQID NO: 13) or c) a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14).

The term “subject” as used herein refers to any animal having a diseaseor condition which requires treatment. The subject may be a human, ormay be a domestic or companion animal. While it is particularlycontemplated that the peptides of the invention are suitable for use inthe treatment of livestock species, such as poultry including chickens,ducks, geese and turkeys, it is also envisaged that such peptides willbe suitable for the treatment of humans and companion animals such asdogs and cats, and other domestic animals such as horses, cattle andsheep, or zoo animals such as non-human primates, felids, canids,bovids, and ungulates.

Generally, the term “treating”, “treatment” and the like are used hereinto mean affecting a subject, tissue or cell to obtain a desiredpharmacological and/or physiological effect. “Treating” as used hereincovers any treatment of infection in a vertebrate and includes:inhibiting the infection, i.e. arresting its development; or relievingor ameliorating the effects of the infection, ie. cause regression ofthe effects of the infection. “Preventing” is used herein to meanpreventing the infection from occurring in a subject who may bepredisposed to the infection, but has not yet been diagnosed as havingthe infection

The methods of this invention may involve the administration of one ormore peptides in an amount sufficient to prevent or treat Campylobacterinfection.

As used herein, the term “sufficient amount” means an amount of the oneor more peptides of the present invention effective to yield a desiredresponse, for example to prevent or treat an infection in subject whichis susceptible to infection by administration of the peptides of theinvention.

The specific “sufficient amount” will of course vary with such factorsas the particular infection being treated, the physical condition andclinical history of the subject, the type of subject being treated, theduration of the treatment, the nature of concurrent therapy (if any),and the specific formulations employed and the structure of the peptidesor fragments or variants thereof.

4. Compositions

The peptides of the invention may be contacted with the Campylobacterspp. in the form of a composition. The peptides of the invention mayalso be administered to a subject as a pharmaceutical compositioncomprising one or more peptides of the invention and a pharmaceuticallyacceptable carrier.

As used herein, a “pharmaceutical acceptable carrier” is apharmaceutically acceptable solvent, suspending agent, excipient orvehicle for delivering peptides to a subject. The carrier may be liquidor solid, and is selected with the planned manner of administration inmind.

Pharmaceutically acceptable carriers include magnesium carbonate,titanium dioxide, lactose, mannitol and other sugars, talc, milkprotein, gelatin, starch, vitamins, cellulose and its derivatives,animal and vegetable oils, polyethylene glycols and solvents, such assterile water, alcohols, glycerol and polyhydric alcohols, non-toxicexcipients, including salts, preservatives, buffers and the like, asdescribed, for instance, in Remington's Pharmaceutical Sciences, 20thed. Williams & Wilkins (2000) and The British National Formulary 43rded. (British Medical Association and Royal Pharmaceutical Society ofGreat Britain, 2002; http://bnf.rhn.net). The pH and exact concentrationof the various components of the pharmaceutical composition are adjustedaccording to routine skills in the art. See Goodman and Gilman's ThePharmacological Basis for Therapeutics (7th ed., 1985).

The specific dose level of the peptides or compositions of the inventionfor any particular subject will depend upon a variety of factorsincluding the activity of the specific peptide employed, the age, bodyweight, general health, sex, diet, time of administration, route ofadministration, rate of excretion, drug combination and the severity ofthe particular infection.

For in vitro use the peptides may be added or dissolved in anappropriate biologically acceptable buffer and added to a cell ortissue. Biologically acceptable buffers include TPS, saline and PBS.

The peptides of the invention may be used as a component of or indeveloping vaccines for Campylobacter spp infection in humans or poultryor other animals. There are several routes available for deliveringvaccines as would be understood by the person skilled in the art. In oneembodiment peptides of the invention are used to identify a bacterialreceptor for use in a sub-unit vaccine. In this embodiment a receptor towhich one or more of the peptides binds is identified by bringingCampylobacter spp into contact with one or more said peptides, allowingbinding to take place and identifying the receptor. The peptide of theinvention may be immobilised to a solid support such as a filter, beads,a column, dipstick or gel, or may be part of a fusion protein or part ofthe phage coat. The receptor so-identified is isolated and/orsynthesised in a manner known to the person skilled in the art and thenused as the antigen component of a sub-unit vaccine. Preparation of thevaccine and suitable vehicles and components such as adjuvants are wellknown to the person skilled in the art. In another embodiment thepeptides of the invention may be used as components of a vaccine such asin a peptide-based vaccine, which may utilise one or morephage-displayed peptides of the invention. Equally an attenuatedbacterial strain may display the peptide and in this regard Wyszynska etal., 2004 describes the oral administration of chickens with anavirulent Salmonella accine strain carrying Campylobacter antigens.

Any convenient method of delivering the polypeptides to a subject isenvisaged. In one embodiment one or more peptides of the invention isexpressed in a vector in plants (an example is provided by Fang et al.2006). The transgenic plant (e.g. grain etc) expressing the therapeuticpeptide is fed to poultry. In another embodiment the delivery vehicle isas described by Lazarev et al. 2004. In this embodiment a recombinantplasmid vector is prepared and administered to chickens as an aerosol.

It will be apparent to the person skilled in the art that while theinvention has been described in some detail for the purposes of clarityand understanding, various modifications and alterations to theembodiments and methods described herein may be made without departingfrom the scope of the inventive concept disclosed in this specification.

5. Methods of Diagnosis

As described above, the inventors have found the peptides describedherein are capable of diagnosing Campylobacter spp infection.Accordingly the present invention relates to a method of diagnosing aCampylobacter spp. infection in a subject comprising:

1) providing a sample from the subject;2) contacting the sample with one or more peptides under conditionswhich permit binding of the one or more peptides to Campylobacter spp.;and3) determining if the one or more peptides bind to a Campylobacter spp.in the sample, wherein the one or more peptides are selected from thegroup consisting of:

-   -   a) a peptide comprising the amino acid sequence EGVLGAALSAFSFDS        (SEQ ID NO: 1) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection; b) a peptide comprising        the amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or a        fragment thereof which is capable of diagnosing Campylobacter        spp infection;    -   c) a peptide comprising the amino acid sequence STALPLWSNYSYDSA        (SEQ ID NO: 3) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection; d) a peptide comprising        the amino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO: 4) or a        fragment thereof which is capable of diagnosing Campylobacter        spp infection;    -   e) a peptide comprising the amino acid sequence KAIAFQSSPGSPVLL        (SEQ ID NO: 5) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   f) a peptide comprising the amino acid sequence TCNLSDYTLPRARVL        (SEQ ID NO: 6) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection; g) a peptide comprising        the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or a        fragment thereof which is capable of diagnosing Campylobacter        spp infection; h) a peptide comprising the amino acid sequence        VPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof which is        capable of diagnosing Campylobacter spp infection;    -   i) a peptide comprising the amino acid sequence SRPIARFYTWSQNTT        (SEQ ID NO: 9) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   j) a peptide comprising the amino acid sequence FSPFRISELVYTLHP        (SEQ ID NO: 10) or a fragment thereof which is capable        diagnosing Campylobacter spp infection;    -   k) a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ        (SEQ ID NO: 11) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   l) a peptide comprising the amino acid sequence GRFLIRVTSSPLGPD        (SEQ ID NO: 12) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   m) a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ        (SEQ ID NO: 13) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   n) a peptide comprising the amino acid sequence FLIDSPLASIGPTSM        (SEQ ID NO: 14) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   o) a peptide comprising the amino acid sequence FMIDSPLASIGPTSM        (SEQ ID NO: 15) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   p) a peptide comprising the amino acid sequence FLSDPPAPPTSPGVV        (SEQ ID NO: 16) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   q) a peptide comprising the amino acid sequence VLAWFSPLTLESSRL        (SEQ ID NO: 17) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   r) a peptide comprising the amino acid sequence VIDLSGTRKSSSGTM        (SEQ ID NO: 18) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   s) a peptide comprising the amino acid sequence VRKTTSHPPSYALLH        (SEQ ID NO: 19) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   t) a peptide comprising the amino acid sequence TPPYRAALATPVLLL        (SEQ ID NO: 20) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   u) a peptide comprising the amino acid sequence LSAPSPMFLPPVNPH        (SEQ ID NO: 21) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   v) a peptide comprising the amino acid sequence HRPVKTPANAPTTMM        (SEQ ID NO: 22) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   w) a peptide comprising the amino acid sequence CFNDPLDIVPPMLLL        (SEQ ID NO: 23) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   x) a peptide comprising the amino acid sequence AHAPCSLFFPLSLRP        (SEQ ID NO: 24) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   y) a peptide comprising the amino acid sequence KALYALHVPSMQVFA        (SEQ ID NO: 25) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection;    -   z) a peptide comprising the amino acid sequence RPSRWPWQEPLPISI        (SEQ ID NO: 26) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection; and        aa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP        (SEQ ID NO: 27) or a fragment thereof which is capable of        diagnosing Campylobacter spp infection.

In one embodiment the method employs a peptide comprising the amino acidsequence LPFNLAKPELYIFVQ (SEQ ID NO: 11).

In one embodiment the peptides may be used for diagnosis by way ofdetection of binding to bacteria of Campylobacter spp. Morespecifically, the method of “detecting” binding partner may comprisecontacting a sample putatively containing bacteria of Campylobacter spp.with peptides which have been detectably labelled. In an embodiment thepeptide which binds Campylobacter spp. may be one of a plurality ofcapture agents immobilized on an array. For example, a peptide can bedetectably labelled with biotin and then contacted with the sample,thereby allowing any bacteria of Campylobacter spp. to be bound by thelabelled peptides. The presence of the bacteria of interest at aparticular location, such as that corresponding to a particular peptideserving as one of the capture agents in the array, can be determined byaddition of streptavidin or avidin, which is then detected by astreptavidin or avidin specific antibody conjugated to a detectablelabel. Other types of detectable labelling of the peptides can also beemployed, including, but not limited to, fluorescent Cy3 and Cy5 labels,gold particles, and radiolabels.

As an alternative to biotin, the peptides may be labelled bychemiluminescence, enhanced chemiluminescence, or a radiolabel.Alternatively, a secondary antibody may be labelled with, for example,horseradish peroxidase or another detectable enzyme or label allowingcolorimetric detection of the peptide complex. Other methods of labelingand detecting proteins are known to persons skilled in the art.

In an embodiment the peptides of the invention may be incorporated intoa phage display library. The phage display library may be used forhigh-throughput screening of protein interactions and so detect thepresence of a receptor for the peptide on the surface of Campylobacterspp. Methods for introducing a peptide to a phage display library arewell understood by the person skilled in the art and described, forexample, by Smith & Petrenko (1997). Briefly, the methods involveligation of a target DNA fragment into genes encoding the coat of aphage such as into the pIII or pVIII of a filamentous phage. Thefilamentous phage strains M13, fd and f1 are commonly used as vectors.The introduced DNA fragment is expressed on the surface of the phageparticle as part of the coat protein. If several DNA fragments areincorporated into the gene then this becomes a library of those DNAfragments. The phage gene and inserted DNA is then transformed intobacterial cells such as male E. coli bacterial cells, in particular TG1E. coli cells. The phage particles will not be released upon maturationof the bacterial cells until they are infected with a helper phage butthen will display the relevant protein fragment as part of their outercoats. An assay may also be based upon the possibility that only asample containing Campylobacter spp. can serve as a suitable host forthe phage and therefore that amplification will only take place when abacterium of Campylobacter spp. is present in the sample. For example,Biotec Laboratories (Ipswich, UK) owns Phage Amplification Technologywhich has the potential for application to a number of differentbacteria using the presence or absence of phage amplification for thediagnosis of infection. In this system a phage infects the bacteria inquestion and a potent viricide destroys all phages that have notinfected a bacterium. The phage continues replication in the viablebacterial cells and are released by cell lysis to reinfectnon-pathogenic sensor cells. Zones of clearing (plaques) on a lawn ofsensor cells signify a positive result in such a test.

EXAMPLES

The invention will now be described in detail by way of reference onlyto the following non-limiting examples and drawings.

Growth of Campylobacter jejuni

Poultry isolates of C. jejuni were provided by Dr. Pat Blackall (QDPI,Australia) and C. jejuni ACM 3393 (NCTC11351) was purchased from theAustralian Collection of Microorganisms (Queensland, Australia). C.jejuni was grown on either pre-purchased Campylobacter agar plates(Oxoid, Australia) or blood agar plates [40 g/L Blood Agar Base #2(Oxoid), 5% (v/v) defibrinated horse blood (Oxoid), and CampylobacterGrowth Supplement (0.25 g/L sodium pyruvate, 0.25 g/L sodiumbetabisulphite and 0.25 g/L ferrous sulphate; Oxoid)]. A microaerophilicatmosphere was provided by CampyGen Sachets (Oxoid) in 2.5 L anaerobejars or alternatively by GasPak E2 Campy Pouches (BD Biosciences).Cultures were grown for 1-2 d at 37° C.

For growth in liquid media, C. jejuni was resuspended in Nutrient BrothNo. 2 (consists of 10 g/L Lab-Lemco powder, 10 g/L peptone and 5 g/Lsodium chloride; Oxoid) supplemented with Campylobacter GrowthSupplement (0.25 g/L sodium pyruvate, 0.25 g/L sodium betabisulphite and0.25 g/L ferrous sulphate; Oxoid). A microaerophilic environment wasprovided by GasPak E2 Campy Pouches (BD Biosciences) and cultures weregrown for 1-2 d at 37° C. and 180 rpm.

Affinity Selection

The f88-4/15-mer peptide phage-display library (provided by Dr. G. P.Smith, University of Missouri-Columbia, USA) was used to affinity selectfor phage peptides binding to the outer surface of C. jejuni. Thislibrary consists of filamentous fd-tet phage displaying random 15-merpeptides fused to 150-300 copies of major coat protein pVIII (Scott &Smith, 1990) and contained a complexity of 2×10⁹ peptidevariants/mL.

FIG. 1 shows the selection schemes for isolating phage clones that boundto C. jejuni. In Selection Scheme A (FIG. 1), the phage-display librarywas directly selected against C. jejuni strain ACM 3393, resulting inPool A phage. In brief: 10¹° transducing units (TU; Smith & Scott, 1993)of the f88-4/15-mer phage library was incubated with 10⁹ CFU of C.jejuni (strain ACM 3393) resuspended in a final volume of 3 mL PBSg(phosphate buffered saline pH 7.0 with 0.1% gelatin). This C.jejuni-phage solution was kept in suspension by agitation on an orbitalshaker at room temperature in a petri dish. After 20 min, phage bindingto C. jejuni was separated from non-binding phage in solution by aseries of washing and centrifugation steps (3,000 rpm for 2 min) usingeither 1 mL of PBSg (pH 7.0) or TBST (TBS pH 7.5 containing 0.5% Tween20) as parallel experiments (PBSg washed or TBST washed in FIG. 1). Thephage remaining bound to C. jejuni was eluted from the pelleted C.jejuni by the addition of elution buffer (0.1 N HCl, pH 2.2 withglycine; 1 g/L bovine serum albumin) for 10 min at room temperature andimmediately neutralised with 1 M Tris-Cl (pH 9.0). The phage wasamplified by infecting “starved” Escherichia coli K91BlueKan cells (Yu &Smith, 1996), twice purified by polyethylene glycol (PEG) precipitationand resuspended in TBS buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl) (Smith& Scott, 1993). This amplified phage was titered in E. coli K91BluKancells prior to being re-applied to freshly prepared C. jejuni cells asabove. Affinity selections against C. jejuni was continued for a totalof three-affinity selections and two amplification steps.

In Selection Scheme B (FIG. 1), a depletion or negative step wasperformed against C. jejuni strain ACM 3393, prior to three rounds ofaffinity selection against C. jejuni strain ACM 3393. This resulted inPool B phage (BT and BP phage; FIG. 1). In Selection Scheme C (FIG. 1),two depletion/negative steps were performed against C. jejuni strain ACM3393, prior to three rounds of affinity selection against C. jejunistrain C338. This resulted in Pool C phage (CT and CP phage; FIG. 1). InSelection Scheme D (FIG. 1), three depletion/negative steps wereperformed (twice against C. jejuni strain ACM 3393 and once againststrain C338), prior to three affinity selections against C. jejunistrain C338.

Phage eluted from the final (3^(rd)) round of each of the selectionschemes were used to infect Escherichia coli K91BlueKan cells. Thesecells were plated on LB (Luria Broth) plates containing 40 mg/Ltetracycline, to select for bacteria containing phage. Bacterialcolonies each containing a single phage population were randomlyselected and propagated for sequencing and testing in antimicrobialassays. Individual phage clones were randomly picked from each of theselection strategies.

DNA Sequencing and Peptide Analysis

Single-stranded DNA was isolated from individual phage clones andsequenced from the 3′ end of the pVIII gene using an ABI Prism 377automated sequencer at the DNA Analysis Facility (Macquarie University,NSW, Australia). The DNA sequences were conceptually translated intoamino acids using the “translate” program on the proteomics server ofthe Swiss Institute of Bioinformatics Expert Protein Analysis System(ExPASy; http://www.expasy.ch). Homologies of the translated peptidesequences with known proteins were obtained using the BLAST program(NCBI; http://www.ncbi.nlm.gov/blast).

Inhibition of Growth of a Campylobacter Species

Representative affinity-selected phage peptides were tested for theirability to inhibit the growth of C. jejuni strains in vitro. Each phageclone was amplified by E. coli infection and twice purified by PEGprecipitation and resuspended in TBS buffer (pH 7.5). Phageconcentrations were calculated as virions/4 using the ultraviolet (UV)absorbance measurements on a spectrophotometer (Smith & Scott, 1993). Aversion of the microdilution susceptibility test was used to determinethe antimicrobial activity of each of the phage-displayed peptides. Inbrief: each of the C. jejuni strains was resuspended to an OD₅₉₅ of 0.2in Nutrient Broth and then diluted to 10⁴-10⁵ CFU/mL in Nutrient Brothcontaining Campylobacter growth supplement. Each well in a microtiterplate was inoculated with 150 μL, of 1-5×10⁵ CFU/mL of bacteria and 45μL of individual phage-displayed peptides in TBS (pH 7.5). Controlsincluded TBS without phage-displayed peptides and TBS containingunselected phage libraries. A microaerophilic environment was providedby GasPak E2 Campy Pouches (BD Biosciences). After 24-48 h at 37° C.without shaking, the optical densities of the bacterial cultures weremeasured at OD₅₉₅ nm in a plate reader (Victor2, Perkin Elmer).

The number of viable bacteria in the 96 well plates was determined byperforming colony counts on the diluted inoculum and plating onto bloodagar plates. Colony counts on blood agar plates were also used todetermine the initial inoculum of bacteria used in the assay. A GramStain Kit was used to check the morphology of C. jejuni after incubationwith the phage peptides.

Overall, ten of the phage clones were found to inhibit the growth of C.jejuni in vitro, as depicted in Table 2. Single-stranded DNA wasisolated from these 10 clones and peptide-encoding region on gene pVIIIsequenced (as shown in Table 2). Two of the clones contained the samesequence, as represented by CP3/3 (FLIDSPLASIGPTSM in Table 2) and CP3/4(FMIDSPLASIGPTSM in Table 2). The remaining six clones encoded uniquepeptide sequences (Table 2).

Using the microdilution susceptibility test, some of the phage cloneswere able to inhibit the growth of C. jejuni in vitro, as shown in Table2. For example, BT3/4 inhibited the growth of C. jejuni in vitro at abacterial concentration of 1×10⁴ CFU/mL. CP3/1 inhibited the growth ofC. jejuni by 97% when the initial bacterial inoculum was 2.8×10⁴ CFU/mLand by 89% when the initial bacterial inoculum was 2.8×10⁴ CFU/mL. CP3/2inhibited the growth of C. jejuni by 92% when the initial bacterialinoculum was 2.8×10⁴ CFU/mL and by 87% when the bacterial inoculum was1.6×10⁵ CFU/mL. In addition, these phage peptides were able to affectthe morphology of C. jejuni as depicted in FIG. 2.

Sequence analysis using BLAST (National Centre of BiotechnologyInformation) indicate that some of the peptides showed similarities toknown proteins in the database. For example AT3/5 from Table 1, showedsimilarity to claudin 1, an integral membrane protein, which is part ofthe tight junction proteins in the gastrointestinal tract of many animalspecies (FIG. 3). In a mouse model of gastrointestinal infection,Helicobacter pylori was found to disrupt the expression of claudin 1.BT3/3 in Table 1 showed similarity to a flagella hook length controlprotein (flgE) from C. jejuni (FIG. 4). This protein is required for C.jejuni motility and virulence in vivo. Together these results indicatethat some of the phage peptides may act by disrupting the ability ofCampylobacter to colonise and invade gastrointestinal cells.

It is to be understood that a reference herein to a prior artpublication does not constitute an admission that the publication formspart of the common general knowledge in the art in Australia, or anyother country.

In the claims which follow and in the preceding description of theinvention, except where the context requires otherwise due to expresslanguage or necessary implication, the word “comprise” or variationssuch as “comprises” or “comprising” is used in an inclusive sense, i.e.to specify the presence of the stated features but not to preclude thepresence or addition of further features in various embodiments of theinvention.

REFERENCES

References cited herein are listed on the following pages, and areincorporated herein by this reference.

-   Altekruse, S. F.; Stern, N. J.; Fields, P. I., and Swerdlow, D. L.    (1999). Campylobacter jejuni—an emerging foodborne pathogen. Emerg    Infect Dis. 28; 5(1):28-35.-   Berrang, M. E.; Buhr, R. J., and Cason, J. A. (2000) Campylobacter    recovery from external and internal organs of commercial broiler    carcass prior to scalding. Poult Sci. 79(2):286-90.-   Bishop-Hurley S. L et al. 2005 Antimicrobial Agents & Chemotherapy    49 (7): 2972-2978).-   Cason, J. A.; Bailey, J. S.; Stern, N. J.; Whittemore, A. D., and    Cox, N. A. (1997) Relationship between aerobic bacteria, salmonellae    and Campylobacter on broiler carcasses. Poult Sci. 76(7):1037-41.-   Denis, M.; Refregier-Petton, J.; Laisney, M. J.; Ermel, G., and    Salvat, G. (2001) Campylobacter contamination in French chicken    production from farm to consumers. Use of a PCR assay for detection    and identification of Campylobacter jejuni and Camp. coli. J Appl    Microbiol. 91(2):255-67.-   Dill, D.; Stanker, L. H.; Young, C. R. 1999. Detection of salmonella    in poultry using a silicon chip-based biosensor. J. Biochem.    Biophys. Methods 41: 61-67.-   Evans, S. J. and Sayers, A. R. (2000) A longitudinal study of    campylobacter infection of broiler flocks in Great Britain. Prey Vet    Med. 46(3):209-23.-   Fang, Z. D.; Laskey, J. G.; Huang, S.; Bilyeu, K. D.; Morris, R. O.;    Schmidt, F. J.; English, J. T. (2006) Combinatorially selected    defense peptides protect plant roots from pathogen infection. PNAS    103 (49): 18444-9.-   Ge, B.; White, D. G.; McDermott, P. F.; Girard, W.; Zhao, S.;    Hubert, S., and Meng, J. (2003) Antimicrobial-resistant    Campylobacter species from retail raw meats. Appl Environ Microbiol.    69(5): 3005-7.-   Gupta, A.; Nelson, J. M.; Barrett, T. J.; Tauxe, R. V.; Rossiter, S.    P.; Friedman, C. R.; Joyce, K. W.; Smith, K. E.; Jones, T. F.;    Hawkins, M. A.; Shiferaw, B.; Beebe, J. L.; Vugia, D. J.;    Rabatsky-Ehr, T.; Benson, J. A.; Root, T. P., and    Angulo, F. J. (2004) Antimicrobial resistance among Campylobacter    strains, United States, 1997-2001. Emerg Infect Dis. 10(6): 1102-9.-   Hendrixson, D. R.; DiRita, V. J. 2003. Transcription of sigma    54-dependent but not sigma 28-dependent flagellar genes in    Campylobacter jejuni is associated with formation of the flagellar    secretory apparatus. Mol. Microbiol. 50 (2): 687-702.-   Lazarev, V. N.; Stipkovits, L.; Biro, J.; Miklodi, D.;    Shkarupeta, M. M.; Titova, G. A.; Akopian, T. A.;    Govorun, V. M. 2004. Induced expression of the antimicrobial peptide    melittin inhibits experimental infection by Mycoplasma gallisepticum    in chickens. Microbes and Infection 6: 536-541.-   Morishita, T. Y.; Aye, P. P.; Harr, B. S.; Cobb, C. W., and    Clifford, J. R. (1997) Evaluation of an avian-specific probiotic to    reduce the colonization and shedding of Campylobacter jejuni in    broilers. Avian Dis. 41(4):850-5.-   Musgrove, M. T.; Cason, J. A.; Fletcher, D. L.; Stern, N. J.;    Cox, N. A., and Bailey, J. S. (1997) Effect of cloacal plugging on    microbial recovery from partially processed broilers. Poult Sci.    76(3):530-3.-   Northcutt, J. K.; Smith, D. P.; Musgrove, M. T.; Ingram, K. D., and    Hinton, A. Jr. (2005) Microbiological impact of spray washing    broiler carcasses using different chlorine concentrations and water    temperatures. Poult Sci. 84(10):1648-52.-   Prats, G.; Mirelis, B.; Llovet, T.; Munoz, C.; Miro, E., and    Navarro, F. (2000) Antibiotic resistance trends in enteropathogenic    bacteria isolated in 1985-1987 and 1995-1998 in Barcelona.    Antimicrob Agents Chemother. 44(5): 1140-5.-   Rivoal, K.; Denis, M.; Salvat, G.; Colin, P., and Ermel, G. (1999)    Molecular characterization of the diversity of Campylobacter spp.    isolates collected from a poultry slaughterhouse: analysis of    cross-contamination. Lett Appl Microbiol. 29(6):370-4.-   Smith, G. P. and Petrenko, V. A., Phage Display Chem. Rev. 1997, 97,    391-410. Stern, N. J.; Svetoch, E. A.; Eruslanov, B. V.; Kovalev, Y.    N.; Volodina, L. I.; Perelygin, V. V.; Mitsevich, E. V.;    Mitsevich, I. P., and Levchuk, V. P. (2005) Paenibacillus polymyxa    purified bacteriocin to control Campylobacter jejuni in chickens. J    Food Prot. 68(7):1450-3.-   Stewart,J. M., et al (1984) Solid Phase Synthesis (Pierce Chemical    Co., 2^(nd) ed.)-   Wallace, J. S.; Stanley, K. N., and Jones, K. (1998) The    colonization of turkeys by thermophilic campylobacters. J Appl    Microbiol. 85(2):224-30.-   Wren, B. W.; Linton, D.; Dorrell, N., and Karlyshev, A. V. (2001)    Post genome analysis of Campylobacter jejuni. Symp Ser Soc Appl    Microbiol. (30):36S-44S.-   Wyszynska, A.; Rackzko, A.; L is, M.;    Jagusztyn-Krynicka, E. K. 2004. Oral immunisation of chickens with    avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA    gene elicits specific humoral immune response associated with    protection against challenge with wild-type Campylobacter. Vaccine    22: 1379-1389.-   Zhao, C.; Ge, B.; De Villena, J.; Sudler, R.; Yeh, E.; Zhao, S.;    White, D. G.; Wagner, D., and Meng, J. (2001) Prevalence of    Campylobacter spp., Escherichia coli, and Salmonella serovars in    retail chicken, turkey, pork, and beef from the Greater Washington,    D.C., area. Appl Environ Microbiol. 67(12):5431-6.-   Zwick, M. B.; Bonnycastle, L. L.; Noren, K. A.; Venturini, S.;    Leong, E.; Barbas, C. F.; Noren, C. J.; Scott, J. K. 1998 The    maltose-binding protein as a scaffold for monovalent display of    peptides derived from phage libraries. Anal Biochem 264: 87-97.

TABLE 1 Amino acid sequences of the phage-displayed peptides. Phageclones Amino acid sequence SEQ ID NO AT3/3 EGVLGAALSAFSFDS 1 AT3/4QAQPCPNQPDGSVYA 2 AT3/5 STALPLWSNYSYDSA 3 AP3/5 RTFGAKPPNIPFPRR 4 BT3/3KAIAFQSSPGSPVLL 5 BT3/4 TCNLSDYTLPRARVL 6 BT3/7 NFLCPSPYPKVQPGL 7 BP3/5VPESIHKASLVCYRF 8 BP3/9 SRPIARFYTWSQNTT 9 CT3/2 FSPFRISELVYTLHP 10 CT3/4LPFNLAKPELYIFVQ 11 CP3/1 GRFLIRVTSSPLGPD 12 CP3/2 TGSGLYLHQMVYLYQ 13CP3/3 FLIDSPLASIGPTSM 14 CP3/4 FMIDSPLASIGPTSM 15 CP3/5 FLIDSPLASIGPTSM14 CP3/6 FMIDSPLASIGPTSM 15 DP3/5 FLSDPPAPPTSPGVV 16 CP2/5VLAWFSPLTLESSRL 17 CP3/8 VIDLSGTRKSSSGTM 18 CP3/9 VRKTTSHPPSYALLH 19CP3/12 TPPYRAALATPVLLL 20 CT3/6 LSAPSPMFLPPVNPH 21 CT3/7 HRPVKTPANAPTTMM22 CT3/9 CFNDPLDIVPPMLLL 23 AT4/3 AHAPCSLFFPLSLRP 24 AT4/5KALYALHVPSMQVFA 25 AT4/8 RPSRWPWQEPLPISI 26 AT4/2 KVQIIPKDTLAPLPP 27

TABLE 2 Amino acid sequences of the phage-displayed peptides and theirantimicrobial activities against C. jejuni strain C338 % inhibitionPhage clones Amino acid sequences of growth BT3/4 TCNLSDYTLPRARVL 60%CP3/1 GRFLIRVTSSPLGPD 96.7% CP3/2 TGSGLYLHQMVYLYQ 92% CP3/3FLIDSPLASIGPTSM 99.3%

1. An isolated peptide which binds to Campylobacter spp., wherein thepeptide is selected from the group consisting of: a) a peptidecomprising the amino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1) or afragment thereof which is capable of binding to Campylobacter spp; b) apeptide comprising the amino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO:2) or a fragment thereof which is capable of binding to Campylobacterspp; c) a peptide comprising the amino acid sequence STALPLWSNYSYDSA(SEQ ID NO: 3) or a fragment thereof which is capable of binding toCampylobacter spp; d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof which is capable ofbinding to Campylobacter spp; e) a peptide comprising the amino acidsequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereof which iscapable of binding to Campylobacter spp; f) a peptide comprising theamino acid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or a fragment thereofwhich is capable of binding to Campylobacter spp; g) a peptidecomprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or afragment thereof which is capable of binding to Campylobacter spp; h) apeptide comprising the amino acid sequence VPESIHKASLVCYRF (SEQ ID NO:8) or a fragment thereof which is capable of binding to Campylobacterspp; i) a peptide comprising the amino acid sequence SRPIARFYTWSQNTT(SEQ ID NO: 9) or a fragment thereof which is capable of binding toCampylobacter spp; j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capableof binding to Campylobacter spp; k) a peptide comprising the amino acidsequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragment thereof which iscapable of binding to Campylobacter spp; 1) a peptide comprising theamino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragmentthereof which is capable of binding to Campylobacter spp; m) a peptidecomprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or afragment thereof which is capable of binding to Campylobacter spp; n) apeptide comprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO:14) or a fragment thereof which is capable of binding to Campylobacterspp o) a peptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQID NO: 15) or a fragment thereof which is capable of binding toCampylobacter spp; p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragment thereof which is capableof binding to Campylobacter spp; q) a peptide comprising the amino acidsequence VLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragment thereof which iscapable of binding to Campylobacter spp; r) a peptide comprising theamino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragmentthereof which is capable of binding to Campylobacter spp; s) a peptidecomprising the amino acid sequence VRKTTSHPPSYALLH (SEQ ID NO: 19) or afragment thereof which is capable of binding to Campylobacter spp; t) apeptide comprising the amino acid sequence TPPYRAALATPVLLL (SEQ ID NO:20) or a fragment thereof which is capable of binding to Campylobacterspp; u) a peptide comprising the amino acid sequence LSAPSPMFLPPVNPH(SEQ ID NO: 21) or a fragment thereof which is capable of binding toCampylobacter spp; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof binding to Campylobacter spp; w) a peptide comprising the amino acidsequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragment thereof which iscapable of binding to Campylobacter spp; x) a peptide comprising theamino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragmentthereof which is capable of binding to Campylobacter spp; y) a peptidecomprising the amino acid sequence KALYALHVPSMQVFA (SEQ ID NO: 25) or afragment thereof which is capable of binding to Campylobacter spp; z) apeptide comprising the amino acid sequence RPSRWPWQEPLPISI (SEQ ID NO:26) or a fragment thereof which is capable of binding to Campylobacterspp; and aa) a peptide comprising the amino acid sequenceKVQIIPKDTLAPLPP (SEQ ID NO: 27) or a fragment thereof which is capableof binding to Campylobacter spp.
 2. An isolated peptide according toclaim 1, wherein the peptide binds specifically to Campylobacter spp. 3.A method of inhibiting growth of or killing a Campylobacter speciescomprising contacting the species with one or more peptides in an amountsufficient to inhibit growth of or kill the species, wherein the one ormore peptides are selected from the group consisting of: a) a peptidecomprising the amino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; b) a peptide comprising the amino acid sequenceQAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; c) a peptidecomprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; e) a peptidecomprising the amino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; f) a peptide comprising the amino acid sequenceTCNLSDYTLPRARVL (SEQ ID NO: 6) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; g) a peptidecomprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; h) a peptide comprising the amino acid sequenceVPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof which is capable ofinhibiting growth of or killing Campylobacter spp; i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; k) a peptidecomprising the amino acid sequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; l) a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; m) a peptidecomprising the amino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; n) a peptide comprising the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; o) a peptidecomprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; q) a peptidecomprising the amino acid sequence VLAWFSPLTLESSRL (SEQ ID NO: 17) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; r) a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; s) a peptidecomprising the amino acid sequence VRKTTSHPPSYALLH (SEQ ID NO: 19) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; t) a peptide comprising the amino acid sequenceTPPYRAALATPVLLL (SEQ ID NO: 20) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; u) a peptidecomprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO: 21) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; w) a peptidecomprising the amino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; x) a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; y) a peptidecomprising the amino acid sequence KALYALHVPSMQVFA (SEQ ID NO: 25) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp; z) a peptide comprising the amino acid sequenceRPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragment thereof which is capableof inhibiting growth of or killing Campylobacter spp; and aa) a peptidecomprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ ID NO: 27) or afragment thereof which is capable of inhibiting growth of or killingCampylobacter spp.
 4. A method according to claim 3 comprisingcontacting the Campylobacter spp. with a peptide comprising the aminoacid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragment thereofwhich is capable of inhibiting growth of or killing Campylobacter spp.5. A method according to claim 3 comprising contacting the Campylobacterspp. with a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ(SEQ ID NO: 13) or a fragment thereof which is capable of inhibitinggrowth of or killing Campylobacter spp.
 6. A method according to claim 3comprising contacting the Campylobacter spp. with a peptide comprisingthe amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragmentthereof which is capable of inhibiting growth of or killingCampylobacter spp.
 7. A method according to claim 3 comprisingcontacting the Campylobacter spp, with a peptide comprising the aminoacid sequence FSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereofwhich is capable of inhibiting growth of or killing Campylobacter spp.8. A method according to claim 3 comprising contacting the Campylobacterspp. with a peptide comprising the amino acid sequence FLSDPPAPPTSPGVV(SEQ ID NO: 16) or a fragment thereof which is capable of inhibitinggrowth of or killing Campylobacter spp.
 9. A method according to any oneof claims 3 to 8, wherein the one or more peptides bind to theCampylobacter species to inhibit growth of or kill the Campylobacterspecies.
 10. A method according to claim 9, wherein the one or morepeptides bind specifically to the Campylobacter species to inhibitgrowth of or kill the Campylobacter species.
 11. A method according toany one of claims 3 to 10, wherein the Campylobacter spp, isCampylobacter jejuni.
 12. A method according to any one of claims 3 to10, wherein the Campylobacter spp. is Campylobacter coll.
 13. A methodaccording to any one of claims 3 to 12, wherein the method comprisesinhibiting growth of or killing Campylobacter spp. in a solution.
 14. Amethod according to any one of claims 3 to 12, wherein the methodcomprises inhibiting growth of or killing Campylobacter spp. on asurface.
 15. A method of preventing a Campylobacter spp. infection in asubject comprising administering to the subject one or more peptides inan amount sufficient to prevent infection in the subject, wherein theone or more peptides are selected from the group consisting of: a) apeptide comprising the amino acid sequence EGVLGAALSAFSFDS (SEQ IDNO: 1) or a fragment thereof which is capable of preventingCampylobacter spp infection; b) a peptide comprising the amino acidsequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereof which iscapable of preventing Campylobacter spp infection; c) a peptidecomprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or afragment thereof which is capable of preventing Campylobacter .sppinfection; d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof which is capable ofpreventing Campylobacter spp infection; e) a peptide comprising theamino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereofwhich is capable of preventing Campylobacter spp infection; f) a peptidecomprising the amino acid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or afragment thereof which is capable of preventing Campylobacter sppinfection; g) a peptide comprising the amino acid sequenceNFLCPSPYPKVQPGL (SEQ ID NO: 7) or a fragment thereof which is capable ofpreventing Campylobacter spp infection; h) a peptide comprising theamino acid sequence VPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereofwhich is capable of preventing Campylobacter spp infection; i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or afragment thereof which is capable of preventing Campylobacter sppinfection; j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capablepreventing Campylobacter spp infection; k) a peptide comprising theamino acid sequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragmentthereof which is capable of preventing Campylobacter spp infection; l) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12) or a fragment thereof which is capable of preventing Campylobacterspp infection; m) a peptide comprising the amino acid sequenceTGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which is capableof preventing Campylobacter spp infection; n) a peptide comprising theamino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragmentthereof which is capable of preventing Campylobacter spp infection; o) apeptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO:15) or a fragment thereof which is capable of preventing Campylobacterspp infection; p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragment thereof which is capableof preventing Campylobacter spp infection; q) a peptide comprising theamino acid sequence VLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragmentthereof which is capable of preventing Campylobacter spp infection; r) apeptide comprising the amino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO:18) or a fragment thereof which is capable of preventing Campylobacterspp infection; s) a peptide comprising the amino acid sequenceVRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragment thereof which is capableof preventing Campylobacter spp infection; t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20) or a fragmentthereof which is capable of preventing Campylobacter spp infection; u) apeptide comprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO:21) or a fragment thereof which is capable of preventing Campylobacterspp infection; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof preventing Campylobacter spp infection; w) a peptide comprising theamino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragmentthereof which is capable of preventing Campylobacter spp infection; x) apeptide comprising the amino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO:24) or a fragment thereof which is capable of preventing Campylobacterspp infection; y) a peptide comprising the amino acid sequenceKALYALHVPSMQVFA (SEQ ID NO: 25) or a fragment thereof which is capableof preventing Campylobacter spp infection; z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragmentthereof which is capable of preventing Campylobacter spp infection; andaa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ IDNO: 27) or a fragment thereof which is capable of preventingCampylobacter spp infection.
 16. A method according to claim 15comprising contacting the Campylobacter spp. with a peptide comprisingthe amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragmentthereof which is capable of preventing Campylobacter spp. infection. 17.A method according to claim 15 comprising contacting the Campylobacterspp. with a peptide comprising the amino acid sequence TGSGLYLHQMVYLYQ(SEQ ID NO: 13) or a fragment thereof which is capable of preventingCampylobacter spp. infection.
 18. A method according to claim 15comprising contacting the Campylobacter spp. with a peptide comprisingthe amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragmentthereof which is capable of preventing Campylobacter spp. infection. 19.A method according to claim 15 comprising contacting the Campylobacterspp. with a peptide comprising the amino acid sequence FSPFRISELVYTLHP(SEQ ID NO: 10) or a fragment thereof which is capable of preventingCampylobacter spp. infection.
 20. A method according to claim 15comprising contacting the Campylobacter spp. with a peptide comprisingthe amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragmentthereof which is capable of preventing Campylobacter spp. infection. 21.A method of treating a Campylobacter spp. infection in a subjectcomprising administering to the subject one or more peptides in anamount sufficient to treat the infection in the subject, wherein the oneor more peptides are selected from the group consisting of: a) a peptidecomprising the amino acid sequence EGVLGAALSAFSFDS (SEQ ID NO: 1) or afragment thereof which is capable of treating Campylobacter sppinfection; b) a peptide comprising the amino acid sequenceQAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereof which is capable oftreating Campylobacter spp infection; c) a peptide comprising the aminoacid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or a fragment thereof whichis capable of treating Campylobacter spp infection; d) a peptidecomprising the amino acid sequence RTFGAKPPNIPFPR1Z. (SEQ ID NO: 4) or afragment thereof which is capable of treating Campylobacter sppinfection; e) a peptide comprising the amino acid sequenceKAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereof which is capable oftreating Campylobacter spp infection; f) a peptide comprising the aminoacid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or a fragment thereof whichis capable of treating Campylobacter spp infection; g) a peptidecomprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or afragment thereof which is capable of treating Campylobacter sppinfection; h) a peptide comprising the amino acid sequenceVPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof which is capable oftreating Campylobacter spp infection; i) a peptide comprising the aminoacid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or a fragment thereof whichis capable of treating Campylobacter spp infection; j) a peptidecomprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO: 10) or afragment thereof which is capable treating Campylobacter spp infection;k) a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ (SEQ IDNO: 11) or a fragment thereof which is capable of treating Campylobacterspp infection; l) a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragment thereof which is capableof treating Campylobacter spp infection; m) a peptide comprising theamino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragmentthereof which is capable of treating Campylobacter spp infection; n) apeptide comprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO:14) or a fragment thereof which is capable of treating Campylobacter sppinfection; o) a peptide comprising the amino acid sequenceFMIDSPLASIGPTSM (SEQ ID NO: 15) or a fragment thereof which is capableof treating Campylobacter spp infection; p) a peptide comprising theamino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragmentthereof which is capable of treating Campylobacter spp infection; q) apeptide comprising the amino acid sequence VLAWFSPLTLESSRL (SEQ ID NO:17) or a fragment thereof which is capable of treating Campylobacter sppinfection; r) a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragment thereof which is capableof treating Campylobacter spp infection; s) a peptide comprising theamino acid sequence VRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragmentthereof which is capable of treating Campylobacter spp infection; t) apeptide comprising the amino acid sequence TPPYRAALATPVLLL (SEQ ID NO:20) or a fragment thereof which is capable of treating Campylobacter sppinfection; u) a peptide comprising the amino acid sequenceLSAPSPMFLPPVNPH (SEQ ID NO: 21) or a fragment thereof which is capableof treating Campylobacter spp infection; v) a peptide comprising theamino acid sequence HRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragmentthereof which is capable of treating Campylobacter spp infection; w) apeptide comprising the amino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO:23) or a fragment thereof which is capable of treating Campylobacter sppinfection; x) a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragment thereof which is capableof treating Campylobacter spp infection; y) a peptide comprising theamino acid sequence KALYALHVPSMQVFA (SEQ ID NO: 25) or a fragmentthereof which is capable of treating Campylobacter spp infection; z) apeptide comprising the amino acid sequence RPSRWPWQEPLPISI (SEQ ID NO:26) or a fragment thereof which is capable of treating Campylobacter sppinfection; and aa) a peptide comprising the amino acid sequenceKVQIIPKDTLAPLPP (SEQ ID NO: 27) or a fragment thereof which is capableof treating Campylobacter spp infection.
 22. A method according to claim21 comprising contacting the Campylobacter spp. with a peptidecomprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or afragment thereof which is capable of treating Campylobacter app.infection.
 23. A method according to claim 21 comprising contacting theCampylobacter spp. with a peptide comprising the amino acid sequenceTGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which is capableof treating Campylobacter spp. infection.
 24. A method according toclaim 21 comprising contacting the Campylobacter spp. with a peptidecomprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or afragment thereof which is capable of treating Campylobacter app.infection.
 25. A method according to claim 21 comprising contacting theCampylobacter spp. with a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capableof treating Campylobacter spp. infection.
 26. A method according toclaim 21 comprising contacting the Campylobacter spp. with a peptidecomprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16) or afragment thereof which is capable of treating Campylobacter spp.infection.
 27. A method of diagnosing a Campylobacter spp. infection ina subject comprising: 1) providing a sample from the subject; 2)contacting the sample with one or more peptides under conditions whichpermit binding of the one or more peptides to Campylobacter sp.; and 3)determining if the one or more peptides bind to a Campylobacter spp. inthe sample, wherein the one or more peptides are selected from the groupconsisting of: a) a peptide comprising the amino acid sequenceEGVLGAALSAFSFDS (SEQ ID NO: 1) or a fragment thereof which is capable ofdiagnosing Campylobacter spp infection; b) a peptide comprising theamino acid sequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereofwhich is capable of diagnosing Campylobacter spp infection; c) a peptidecomprising the amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or afragment thereof which is capable of diagnosing Campylobacter sppinfection; d) a peptide comprising the amino acid sequenceRTFGAKPPNIPFPRR (SEQ ID NO: 4) or a fragment thereof which is capable ofdiagnosing Campylobacter spp infection; e) a peptide comprising theamino acid sequence KAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereofwhich is capable of diagnosing Campylobacter spp infection; f) a peptidecomprising the amino acid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or afragment thereof which is capable of diagnosing Campylobacter sppinfection; g) a peptide comprising the amino acid sequenceNFLCPSPYPKVQPGL (SEQ ID NO: 7) or a fragment thereof which is capable ofdiagnosing Campylobacter spp infection; h) a peptide comprising theamino acid sequence VPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereofwhich is capable of diagnosing Campylobacter spp infection; i) a peptidecomprising the amino acid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or afragment thereof which is capable of diagnosing Campylobacter sppinfection; j) a peptide comprising the amino acid sequenceFSPFRISELVYTLHP (SEQ ID NO: 10) or a fragment thereof which is capablediagnosing Campylobacter spp infection; k) a peptide comprising theamino acid sequence LPFNLAKPELYIFVQ (SEQ ID NO: 11) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; l) apeptide comprising the amino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO:12) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; m) a peptide comprising the amino acid sequenceTGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; n) a peptide comprising theamino acid sequence FLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; o) apeptide comprising the amino acid sequence FMIDSPLASIGPTSM (SEQ ID NO:15) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; p) a peptide comprising the amino acid sequenceFLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; q) a peptide comprising theamino acid sequence VLAWFSPLTLESSRL (SEQ ID NO: 17) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; r) apeptide comprising the amino acid sequence VIDLSGTRKSSSGTM (SEQ ID NO:18) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; s) a peptide comprising the amino acid sequenceVRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; t) a peptide comprising theamino acid sequence TPPYRAALATPVLLL (SEQ ID NO: 20) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; u) apeptide comprising the amino acid sequence LSAPSPMFLPPVNPH (SEQ ID NO:21) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; v) a peptide comprising the amino acid sequenceHRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; w) a peptide comprising theamino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO: 23) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; x) apeptide comprising the amino acid sequence AHAPCSLFFPLSLRP (SEQ ID NO:24) or a fragment thereof which is capable of diagnosing Campylobacterspp infection; y) a peptide comprising the amino acid sequenceKALYALHVPSMQVFA (SEQ ID NO: 25) or a fragment thereof which is capableof diagnosing Campylobacter spp infection; z) a peptide comprising theamino acid sequence RPSRWPWQEPLPISI (SEQ ID NO: 26) or a fragmentthereof which is capable of diagnosing Campylobacter spp infection; andaa) a peptide comprising the amino acid sequence KVQIIPKDTLAPLPP (SEQ IDNO: 27) or a fragment thereof which is capable of diagnosingCampylobacter spp infection.
 28. A method according to claim 27comprising contacting the sample with a peptide comprising the aminoacid sequence FMIDSPLASIGPTSM (SEQ ID NO: 15) or a fragment thereofwhich is capable of diagnosing Campylobacter spp infection.
 29. A methodaccording to claim 28 comprising contacting the sample with a peptidecomprising the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16) or afragment thereof which is capable of diagnosing Campylobacter sppinfection.
 30. A method according to any one of claims 15 to 29, whereinthe Campylobacter spp. is Campylobacter jejuni.
 31. A method accordingto any one of claims 15 to 29, wherein the Campylobacter spp. isCampylobacter
 32. A method according to any one of claims 15 to 31,wherein the subject in selected from the group consisting of humans,poultry, domesticated animals or agricultural animals.
 33. A methodaccording to claim 32, wherein poultry comprises chickens, ducks, geeseor turkeys.
 34. A method according to claim 32, wherein domesticatedanimals comprise cats or dogs
 35. A method according to claim 32,wherein agricultural animals comprise pigs, cattle or sheep.
 36. Anisolated peptide comprising an amino acid sequence selected from thegroup consisting of: EGVLGAALSAFSFDS (SEQ ID NO: 1); QAQPCPNQPDGSVYA(SEQ ID NO: 2); STALPLWSNYSYDSA (SEQ ID NO: 3); RTFGAKPPNIPFPRR (SEQ IDNO: 4); KAIAFQSSPGSPVLL (SEQ ID NO: 5); TCNLSDYTLPRARVL (SEQ ID NO: 6);NFLCPSPYPKVQPGL (SEQ ID NO: 7); VPESIHKASLVCYRF (SEQ ID NO: 8);SRPIARFYTWSQNTT (SEQ ID NO: 9); FSPFRISELVYTLHP (SEQ ID NO: 10);LPFNLAKPELYIFVQ (SEQ ID NO: 11); GRFLIRVTSSPLGPD (SEQ ID NO: 12);TGSGLYLHQMVYLYQ (SEQ ID NO: 13); FLIDSPLASIGPTSM (SEQ ID NO: 14)FMIDSPLASIGPTSM (SEQ ID NO: 15); FLSDPPAPPTSPGVV (SEQ ID NO: 16);VLAWFSPLTLESSRL (SEQ ID NO: 17); VIDLSGTRKSSSGTM (SEQ ID NO: 18);VRKTTSHPPSYALLH (SEQ ID NO: 19); TPPYRAALATPVLLL (SEQ ID NO: 20);LSAPSPMFLPPVNPH (SEQ ID NO: 21); HRPVKTPANAPTTMM (SEQ ID NO: 22);CFNDPLDIVPPMLLL (SEQ ID NO: 23); AHAPCSLFFPLSLRP (SEQ ID NO: 24);KALYALHVPSMQVFA (SEQ ID NO: 25); RPSRWPWQEPLPISI (SEQ ID NO: 26); andKVQIIPKDTLAPLPP (SEQ ID NO: 27).
 37. An isolated peptide of 15 to 100amino acid residues comprising an amino acid sequence selected from thegroup consisting of: EGVLGAALSAFSFDS (SEQ ID NO: 1); QAQPCPNQPDGSVYA(SEQ ID NO: 2); STALPLWSNYSYDSA (SEQ ID NO: 3); RTFGAKPPNIPFPRR (SEQ IDNO: 4); KAIAFQSSPGSPVLL (SEQ ID NO: 5); TCNLSDYTLPRARVL (SEQ ID NO: 6);NFLCPSPYPKVQPGL (SEQ ID NO: 7); VPESIHKASLVCYRF (SEQ ID NO: 8);SRPIARFYTWSQNTT (SEQ ID NO: 9); FSPFRISELVYTLHP (SEQ ID NO: 10);LPFNLAKPELYIFVQ (SEQ ID NO: 11); GRFLIRVTSSPLGPD (SEQ ID NO: 12);TGSGLYLHQMVYLYQ (SEQ ID NO: 13); FLIDSPLASIGPTSM (SEQ ID NO: 14)FMIDSPLASIGPTSM (SEQ ID NO: 15); FLSDPPAPPTSPGVV (SEQ ID NO: 16);VLAWFSPLTLESSRL (SEQ ID NO: 17); VIDLSGTRKSSSGTM (SEQ ID NO: 18);VRKTTSHPPSYALLH (SEQ ID NO: 19); TPPYRAALATPVLLL (SEQ ID NO: 20);LSAPSPMFLPPVNPH (SEQ ID NO: 21); HRPVKTPANAPTTMM (SEQ ID NO: 22);CFNDPLDIVPPMLLL (SEQ ID NO: 23); AHAPCSLFFPLSLRP (SEQ ID NO: 24);KALYALHVPSMQVFA (SEQ ID NO: 25); RPSRWPWQEPLPISI (SEQ ID NO: 26); andKVQIIPKDTLAPLPP (SEQ ID NO: 27).
 38. A synthetic peptide comprising anamino acid sequence selected from the group consisting of:EGVLGAALSAFSFDS (SEQ ID NO: 1); QAQPCPNQPDGSVYA (SEQ ID NO: 2);STALPLWSNYSYDSA (SEQ ID NO: 3); RTFGAKPPNIPFPRR (SEQ ID NO: 4);KAIAFQSSPGSPVLL (SEQ ID NO: 5); TCNLSDYTLPRARVL (SEQ ID NO: 6);NFLCPSPYPKVQPGL (SEQ ID NO: 7); VPESIHKASLVCYRF (SEQ ID NO: 8);SRPIARFYTWSQNTT (SEQ ID NO: 9); FSPFRISELVYTLHP (SEQ ID NO: 10);LPFNLAKPELYIFVQ (SEQ ID NO: 11); GRFLIRVTSSPLGPD (SEQ ID NO: 12);TGSGLYLHQMVYLYQ (SEQ ID NO: 13); FLIDSPLASIGPTSM (SEQ ID NO: 14)FMIDSPLASIGPTSM (SEQ ID NO: 15); FLSDPPAPPTSPGVV (SEQ ID NO: 16);VLAWFSPLTLESSRL (SEQ ID NO: 17); VIDLSGTRKSSSGTM (SEQ ID NO: 18);VRKTTSHPPSYALLH (SEQ ID NO: 19); TPPYRAALATPVLLL (SEQ ID NO: 20);LSAPSPMFLPPVNPH (SEQ ID NO: 21); HRPVKTPANAPTTMM (SEQ ID NO: 22);CFNDPLDIVPPMLLL (SEQ ID NO: 23); AHAPCSLFFPLSLRP (SEQ ID NO: 24);KALYALHVPSMQVFA (SEQ ID NO: 25); RPSRWPWQEPLPISI (SEQ ID NO: 26); andKVQIIPKDTLAPLPP (SEQ ID NO: 27).
 39. A composition comprising one ormore peptides, wherein the one of more peptides comprise an amino acidsequence selected from the group consisting of: EGVLGAALSAFSFDS; (SEQ IDNO: 1) QAQPCPNQPDGSVYA; (SEQ ID NO: 2) STALPLWSNYSYDSA; (SEQ ID NO: 3)RTFGAKPPNIPFPRR; (SEQ ID NO: 4) KAIAFQSSPGSPVLL; (SEQ ID NO: 5)TCNLSDYTLPRARVL; (SEQ ID NO: 6) NFLCPSPYPKVQPGL; (SEQ ID NO: 7)VPESIHKASLVCYRF; (SEQ ID NO: 8) SRPIARFYTWSQNTT; (SEQ ID NO: 9)FSPFRISELVYTLHP; (SEQ ID NO: 10) LPFNLAKPELYIFVQ; (SEQ ID NO: 11)GRFLIRVTSSPLGPD; (SEQ ID NO: 12) TGSGLYLHQMVYLYQ; (SEQ ID NO: 13)FLIDSPLASIGPTSM (SEQ ID NO: 14) FMIDSPLASIGPTSM; (SEQ ID NO: 15)FLSDPPAPPTSPGVV; (SEQ ID NO: 16) VLAWFSPLTLESSRL; (SEQ ID NO: 17)VIDLSGTRKSSSGTM; (SEQ ID NO: 18) VRKTTSHPPSYALLH; (SEQ ID NO: 19)TPPYRAALATPVLLL; (SEQ ID NO: 20) LSAPSPMFLPPVNPH; (SEQ ID NO: 21)HRPVKTPANAPTTMM; (SEQ ID NO: 22) CFNDPLDIVPPMLLL; (SEQ ID NO: 23)AHAPCSLFFPLSLRP; (SEQ ID NO: 24) KALYALHVPSMQVFA; (SEQ ID NO: 25)RPSRWPWQEPLPISI; (SEQ ID NO: 26) and KVQIIPKDTLAPLPP. (SEQ ID NO: 27)


40. A pharmaceutical composition comprising one or more peptides and apharmaceutically acceptable carrier, wherein the one or more peptidescomprise an amino acid sequence selected from the group consisting of:EGVLGAALSAFSFDS (SEQ ID NO: 1); QAQPCPNQPDGSVYA (SEQ ID NO: 2);STALPLWSNYSYDSA (SEQ ID NO: 3); RTFGAKPPNIPFPRR (SEQ ID NO: 4);KAIAFQSSPGSPVLL (SEQ ID NO: 5); TCNLSDYTLPRARVL (SEQ ID NO: 6);NFLCPSPYPKVQPGL (SEQ ID NO: 7); VPESIHKASLVCYRF (SEQ ID NO: 8);SRPIARFYTWSQNTT (SEQ ID NO: 9); FSPFRISELVYTLHP (SEQ ID NO: 10);LPFNLAKPELYIFVQ (SEQ ID NO: 11); GRFLIRVTSSPLGPD (SEQ ID NO: 12);TGSGLYLHQMVYLYQ (SEQ ID NO: 13); FLIDSPLASIGPTSM (SEQ ID NO: 14)FMIDSPLASIGPTSM (SEQ ID NO: 15); FLSDPPAPPTSPGVV (SEQ ID NO: 16);VLAWFSPLTLESSRL (SEQ ID NO: 17); VIDLSGTRKSSSGTM (SEQ ID NO: 18);VRKTTSHPPSYALLH (SEQ ID NO: 19); TPPYRAALATPVLLL (SEQ ID NO: 20);LSAPSPMFLPPVNPH (SEQ ID NO: 21); HRPVKTPANAPTTMM (SEQ ID NO: 22);CFNDPLDIVPPMLLL (SEQ ID NO: 23); AHAPCSLFFPLSLRP (SEQ ID NO: 24);KALYALHVPSMQVFA (SEQ ID NO: 25); RPSRWPWQEPLPISI (SEQ ID NO: 26); andKVQIIPKDTLAPLPP (SEQ ID NO: 27).
 41. A fusion protein comprising one ormore peptides, wherein the one or more peptides comprise an amino acidsequence selected from the group consisting of: EGVLGAALSAFSFDS; (SEQ IDNO: 1) QAQPCPNQPDGSVYA; (SEQ ID NO: 2) STALPLWSNYSYDSA; (SEQ ID NO: 3)RTFGAKPPNIPFPRR; (SEQ ID NO: 4) KAIAFQSSPGSPVLL; (SEQ ID NO: 5)TCNLSDYTLPRARVL; (SEQ ID NO: 6) NFLCPSPYPKVQPGL; (SEQ ID NO: 7)VPESIHKASLVCYRF; (SEQ ID NO: 8) SRPIARFYTWSQNTT; (SEQ ID NO: 9)FSPFRISELVYTLHP; (SEQ ID NO: 10) LPFNLAKPELYIFVQ; (SEQ ID NO: 11)GRFLIRVTSSPLGPD; (SEQ ID NO: 12) TGSGLYLHQMVYLYQ; (SEQ ID NO: 13)FLIDSPLASIGPTSM (SEQ ID NO: 14) FMIDSPLASIGPTSM; (SEQ ID NO: 15)FLSDPPAPPTSPGVV; (SEQ ID NO: 16) VLAWFSPLTLESSRL; (SEQ ID NO: 17)VIDLSGTRKSSSGTM; (SEQ ID NO: 18) VRKTTSHPPSYALLH; (SEQ ID NO: 19)TPPYRAALATPVLLL; (SEQ ID NO: 20) LSAPSPMFLPPVNPH; (SEQ ID NO: 21)HRPVKTPANAPTTMM; (SEQ ID NO: 22) CFNDPLDIVPPMLLL; (SEQ ID NO: 23)AHAPCSLFFPLSLRP; (SEQ ID NO: 24) KALYALHVPSMQVFA; (SEQ ID NO: 25)RPSRWPWQEPLPISI; (SEQ ID NO: 26) and KVQIIPKDTLAPLPP. (SEQ ID NO: 27)


42. A fusion protein according to claim 41, wherein the protein furthercomprises a phage coat or part thereof.
 43. A fd-tet phage comprisingone or more peptides, wherein the one or more peptides comprise an aminoacid sequence selected from the group consisting of: EGVLGAALSAFSFDS;(SEQ ID NO: 1) QAQPCPNQPDGSVYA; (SEQ ID NO: 2) STALPLWSNYSYDSA; (SEQ IDNO: 3) RTFGAKPPNIPFPRR; (SEQ ID NO: 4) KAIAFQSSPGSPVLL; (SEQ ID NO: 5)TCNLSDYTLPRARVL; (SEQ ID NO: 6) NFLCPSPYPKVQPGL; (SEQ ID NO: 7)VPESIHKASLVCYRF; (SEQ ID NO: 8) SRPIARFYTWSQNTT; (SEQ ID NO: 9)FSPFRISELVYTLHP; (SEQ ID NO: 10) LPFNLAKPELYIFVQ; (SEQ ID NO: 11)GRFLIRVTSSPLGPD; (SEQ ID NO: 12) TGSGLYLHQMVYLYQ; (SEQ ID NO: 13)FLIDSPLASIGPTSM, (SEQ ID NO: 14) FMIDSPLASIGPTSM; (SEQ ID NO: 15)FLSDPPAPPTSPGVV; (SEQ ID NO: 16) VLAWFSPLTLESSRL; (SEQ ID NO: 17)VIDLSGTRKSSSGTM; (SEQ ID NO: 18) VRKTTSHPPSYALLH; (SEQ ID NO: 19)TPPYRAALATPVLLL; (SEQ ID NO: 20) LSAPSPMFLPPVNPH; (SEQ ID NO: 21)HRPVKTPANAPTTMM; (SEQ ID NO: 22) CFNDPLDIVPPMLLL; (SEQ ID NO: 23)AHAPCSLFFPLSLRP; (SEQ ID NO: 24) KALYALHVPSMQVFA; (SEQ ID NO: 25)RPSRWPWQEPLPISI; (SEQ ID NO: 26) and KVQIIPKDTLAPLPP. (SEQ ID NO: 27)


44. An isolated nucleic acid molecule which encodes a peptide selectedfrom the group consisting of: EGVLGAALSAFSFDS (SEQ ID NO: 1);QAQPCPNQPDGSVYA (SEQ ID NO: 2); STALPLWSNYSYDSA (SEQ ID NO: 3);RTFGAKPPNIPFPRR (SEQ ID NO: 4); KAIAFQSSPGSPVLL (SEQ ID NO: 5);TCNLSDYTLPRARVL (SEQ ID NO: 6); NFLCPSPYPKVQPGL (SEQ ID NO: 7);VPESIHKASLVCYRF (SEQ ID NO: 8); SRPIARFYTWSQNTT (SEQ ID NO: 9);FSPFRISELVYTLHP (SEQ ID NO: 10); LPFNLAKPELYIFVQ (SEQ ID NO: 11);GRFLIRVTSSPLGPD (SEQ ID NO: 12); TGSGLYLHQMVYLYQ (SEQ ID NO: 13);FLIDSPLASIGPTSM (SEQ ID NO: 14), FMIDSPLASIGPTSM (SEQ ID NO: 15);FLSDPPAPPTSPGVV (SEQ ID NO: 16); VLAWFSPLTLESSRL (SEQ ID NO: 17);VIDLSGTRKSSSGTM (SEQ ID NO: 18); VRKTTSHPPSYALLH (SEQ ID NO: 19);TPPYRAALATPVLLL (SEQ ID NO: 20); LSAPSPMFLPPVNPH (SEQ ID NO: 21);HRPVKTPANAPTTMM (SEQ ID NO: 22); CFNDPLDIVPPMLLL (SEQ ID NO: 23);AHAPCSLFFPLSLRP (SEQ ID NO: 24); KALYALHVPSMQVFA (SEQ ID NO: 25);RPSRWPWQEPLPISI (SEQ ID NO: 26); and KVQIIPKDTLAPLPP (SEQ ID NO: 27).45. The use of one or more peptides selected from the group consistingof: a) a peptide comprising the amino acid sequence EGVLGAALSAFSFDS (SEQID NO: 1) or a fragment thereof which is capable of treatingCampylobacter spp infection; b) a peptide comprising the amino acidsequence QAQPCPNQPDGSVYA (SEQ ID NO: 2) or a fragment thereof which iscapable of treating Campylobacter spp infection; c) a peptide comprisingthe amino acid sequence STALPLWSNYSYDSA (SEQ ID NO: 3) or a fragmentthereof which is capable of treating Campylobacter spp infection; d) apeptide comprising the amino acid sequence RTFGAKPPNIPFPRR (SEQ ID NO:4) or a fragment thereof which is capable of treating Campylobacter .sppinfection; e) a peptide comprising the amino acid sequenceKAIAFQSSPGSPVLL (SEQ ID NO: 5) or a fragment thereof which is capable oftreating Campylobacter spp infection; f) a peptide comprising the aminoacid sequence TCNLSDYTLPRARVL (SEQ ID NO: 6) or a fragment thereof whichis capable of treating Campylobacter spp infection; g) a peptidecomprising the amino acid sequence NFLCPSPYPKVQPGL (SEQ ID NO: 7) or afragment thereof which is capable of treating Campylobacter sppinfection; h) a peptide comprising the amino acid sequenceVPESIHKASLVCYRF (SEQ ID NO: 8) or a fragment thereof which is capable oftreating Campylobacter spp infection; i) a peptide comprising the aminoacid sequence SRPIARFYTWSQNTT (SEQ ID NO: 9) or a fragment thereof whichis capable of treating Campylobacter spp infection; j) a peptidecomprising the amino acid sequence FSPFRISELVYTLHP (SEQ ID NO: 10) or afragment thereof which is capable treating Campylobacter spp infection;k) a peptide comprising the amino acid sequence LPFNLAKPELYIFVQ (SEQ IDNO: 11) or a fragment thereof which is capable of treating Campylobacterspp infection; l) a peptide comprising the amino acid sequenceGRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragment thereof which is capableof treating Campylobacter spp infection; m) a peptide comprising theamino acid sequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragmentthereof which is capable of treating Campylobacter spp infection; n) apeptide comprising the amino acid sequence FLIDSPLASIGPTSM (SEQ ID NO:14) or a fragment thereof which is capable of treating Campylobacter sppinfection; o) a peptide comprising the amino acid sequenceFMIDSPLASIGPTSM (SEQ ID NO: 15) or a fragment thereof which is capableof treating Campylobacter spp infection; p) a peptide comprising theamino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO: 16) or a fragmentthereof which is capable of treating Campylobacter spp infection; q) apeptide comprising the amino acid sequence VLAWFSPLTLESSRL (SEQ ID NO:17) or a fragment thereof which is capable of treating Campylobacter sppinfection; r) a peptide comprising the amino acid sequenceVIDLSGTRKSSSGTM (SEQ ID NO: 18) or a fragment thereof which is capableof treating Campylobacter spp infection; s) a peptide comprising theamino acid sequence VRKTTSHPPSYALLH (SEQ ID NO: 19) or a fragmentthereof which is capable of treating Campylobacter spp infection; t) apeptide comprising the amino acid sequence TPPYRAALATPVLLL (SEQ ID NO:20) or a fragment thereof which is capable of treating Campylobacter sppinfection; u) a peptide comprising the amino acid sequenceLSAPSPMFLPPVNPH (SEQ ID NO: 21) or a fragment thereof which is capableof treating Campylobacter spp infection; v) a peptide comprising theamino acid sequence HRPVKTPANAPTTMM (SEQ ID NO: 22) or a fragmentthereof which is capable of treating Campylobacter spp infection; w) apeptide comprising the amino acid sequence CFNDPLDIVPPMLLL (SEQ ID NO:23) or a fragment thereof which is capable of treating Campylobacter sppinfection; x) a peptide comprising the amino acid sequenceAHAPCSLFFPLSLRP (SEQ ID NO: 24) or a fragment thereof which is capableof treating Campylobacter spp infection; y) a peptide comprising theamino acid sequence KALYALHVPSMQVFA (SEQ ID NO: 25) or a fragmentthereof which is capable of treating Campylobacter spp infection; z) apeptide comprising the amino acid sequence RPSRWPWQEPLPISI (SEQ ID NO:26) or a fragment thereof which is capable of treating Campylobacter sppinfection; and aa) a peptide comprising the amino acid sequenceKVQIIPKDTLAPLPP (SEQ ID NO: 27) or a fragment thereof which is capableof treating Campylobacter spp infection in the manufacture of amedicament for the treatment of Campylobacter spp infection in asubject.
 46. Use according to claim 45 wherein the peptide comprises theamino acid sequence GRFLIRVTSSPLGPD (SEQ ID NO: 12) or a fragmentthereof which is capable of treating Campylobacter spp infection. 47.Use according to claim 45 wherein the peptide comprises the amino acidsequence TGSGLYLHQMVYLYQ (SEQ ID NO: 13) or a fragment thereof which iscapable of treating Campylobacter spp infection.
 48. Use according toclaim 45 wherein the peptide comprises the amino acid sequenceFLIDSPLASIGPTSM (SEQ ID NO: 14) or a fragment thereof which is capableof treating Campylobacter spp infection.
 49. Use according to claim 45wherein the peptide comprises the amino acid sequence FSPFRISELVYTLHP(SEQ ID NO: 10) or a fragment thereof which is capable treatingCampylobacter spp infection.
 50. Use according to claim 45 wherein thepeptide comprises the amino acid sequence FLSDPPAPPTSPGVV (SEQ ID NO:16) or a fragment thereof which is capable of treating Campylobacter sppinfection.